WO2023122588A2 - Egfr-cmet–targeted compounds and uses thereof - Google Patents

Egfr-cmet–targeted compounds and uses thereof Download PDF

Info

Publication number
WO2023122588A2
WO2023122588A2 PCT/US2022/082021 US2022082021W WO2023122588A2 WO 2023122588 A2 WO2023122588 A2 WO 2023122588A2 US 2022082021 W US2022082021 W US 2022082021W WO 2023122588 A2 WO2023122588 A2 WO 2023122588A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
acid sequence
region
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/082021
Other languages
English (en)
French (fr)
Other versions
WO2023122588A3 (en
Inventor
Sadaf AGHEVLIAN
Natalie GRINSHTEIN
Ian R. DUFFY
Thomas I. KOSTELNIK
Andrew Grier Buchanan
Yariv Mazor
Srinath Kasturirangan
Qun DU
Chunning YANG
Frank Irvine COMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Pharmaceuticals Inc
AstraZeneca UK Ltd
Original Assignee
Fusion Pharmaceuticals Inc
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP22912656.0A priority Critical patent/EP4452954A2/en
Priority to US18/721,647 priority patent/US20250121104A1/en
Priority to IL313333A priority patent/IL313333A/en
Priority to CN202280092041.0A priority patent/CN118765273A/zh
Priority to CR20240254A priority patent/CR20240254A/es
Priority to AU2022419564A priority patent/AU2022419564A1/en
Priority to MX2024007596A priority patent/MX2024007596A/es
Priority to CA3244030A priority patent/CA3244030A1/en
Application filed by Fusion Pharmaceuticals Inc, AstraZeneca UK Ltd filed Critical Fusion Pharmaceuticals Inc
Priority to KR1020247024103A priority patent/KR20240125970A/ko
Priority to JP2024537033A priority patent/JP2025500944A/ja
Publication of WO2023122588A2 publication Critical patent/WO2023122588A2/en
Publication of WO2023122588A3 publication Critical patent/WO2023122588A3/en
Anticipated expiration legal-status Critical
Priority to CONC2024/0008733A priority patent/CO2024008733A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Non-small cell lung cancer remains the leading cause of cancer-related mortality worldwide. While with the development of EGFR-tyrosine kinase inhibitors (TKIs) the prognosis of advanced NSCLC has significantly improved for certain patients, metastatic NSCLC patients with long-term survival are still rare.
  • TKIs EGFR-tyrosine kinase inhibitors
  • a recent study by Lin et al. has shown that the prevalence of 5-year survival among patients with EGFR-mutant metastatic NSCLC treated with erlotinib or gefitinib is only 14.6%.
  • Anti-EGFR TKIs are susceptible to resistance and the underlying resistant mechanism is long known to be the coexistence of EGFR mutation and cMET overexpression.
  • One promising approach being tested in clinic is amivantamab, a human EGFR-cMET bispecific antibody that has been approved for treating non-small cell lung cancer. Targeting EGFR and cMET receptors increase the specificity of the treatment to cancer cells.
  • the present disclosure relates to compounds (e.g., radioimmunoconjugates) that target both EGFR and cMET, pharmaceutical compositions thereof, and methods of treating cancer using such compounds or pharmaceutical compositions.
  • radioimmunoconjugates do not need to block the receptor function to have therapeutic efficacy; instead they emit radioactive particles (e.g., alpha emitters) that target the surrounding tumor cells within the limited range, thus preventing any off target associated toxicity.
  • EGFR-cMET -targeted compounds e.g., radioimmunoconjugates
  • EGFR-cMET -targeted compounds used for EGFR and cMET overexpressing cancers utilize the ability of EGFR-cMET complex to undergo antibody triggered internalization to deliver the targeted radionuclides inside the cancer cells specifically.
  • Antibody monovalent binding to either of the receptors on normal healthy tissues/cells does not lead to internalization.
  • provided compounds e.g., radioimmunoconjugates
  • exhibit an increased excretion rate e.g., after being administered to a mammal
  • a faster excretion may limit off-target toxicities by limiting the amount of time that the compound stays in a subject.
  • provided compounds exhibit reduced off-target toxicities.
  • A is a chelating moiety or a metal complex thereof
  • B is an antibody or antigen-binding fragment thereof
  • L 2 each independently has the structure of Formula II:
  • X 1 is - OjNR 1 -*, -NR 3 C(O)-*, -C(S)NR'-*, -NR 1 C(S)-*, -(DC(O)NR 1 -*, - NR ⁇ OjO-*, -NR ⁇ OjNR 1 -, -CH 2 -Ph-C(O)NR 1 -*, -NR 1 C(O)-Ph-CH 2 -*, -CH 2 -Ph- NH-C(S)NR'-*, -NR 1 C(S)-NH-Ph-CH 2 -*, -O-, or -NR 1 -, wherein indicates the attachment point to L 3 , and R 1 is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • L 3 is optionally substituted C1-C50 alkyl or optionally substituted C1-C50 heteroalkyl
  • Z 1 is -CH 2 -#, -C(O)-#, -C(S)-#, -OC(O)-#, -C(O)O-#, -NR 2 C(O)-#, -C(O)NR 2 -#, or -NR 2 -#, wherein “#” indicates the attachment point to B, andR 2 is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl, and wherein the antibody or antigen-binding fragment thereof comprises a first antigenbinding domain that is capable of binding epidermal growth factor receptor (EGFR) and a second antigen-binding domain that is capable of binding cMET, wherein the first antigen-binding domain comprises: i. a heavy chain variable (VH) region comprising the following complementarity determining regions (CDRs):
  • VH heavy chain variable
  • HCDR1 having the amino acid sequence of SEQ ID NO: 1
  • HCDR2 having the amino acid sequence of SEQ ID NO: 2
  • HCDR3 having the amino acid sequence of SEQ ID NO: 3, or a variant thereof in which one or two or three amino acids in one or more of HCDR1, HCDR2, and HCDR3 are substituted with another amino acid; and ii. a light chain variable (VL) region comprising the following CDRs:
  • LCDR1 having the amino acid sequence of SEQ ID NO: 4
  • LCDR2 having the amino acid sequence of SEQ ID NO: 5
  • LCDR3 having the amino acid sequence of SEQ ID NO: 6, or a variant thereof in which one or two or three amino acids in one or more of LCDR1, LCDR2, and LCDR3 are substituted with another amino acid.
  • variable A in Formula I is a chelating moiety selected from the group consisting of DOTA (l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid), DOTMA (lR,4R,7R,10R)-a, a’, a”, a”’-tetramethyl-l,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid, DOTAM (1,4,7, 10-tetrakis(carbamoylmethyl)-l, 4, 7,10- tetraazacyclododecane), DOTPA (l,4,7,10-tetraazacyclododecane-l,4,7,10-tetra propionic acid), DO3 AM-acetic acid (2-(4, 7,10-tris(2-amino-2-oxoethyl)- 1,4, 7,10- tetraacetic acid), DO3 AM-
  • the compound is represented by Formula I-a, or a metal complex thereof:
  • Formula I-a wherein Y 1 is -CH 2 OCH 2 (L 2 )n-B, -C(O)(L 2 ) n -B, or -C(S)(L 2 ) n -B and Y 2 is -CH 2 CO 2 H; or wherein Y 1 is H and Y 2 is L ⁇ L ⁇ n-B. In certain embodiments, Y 1 is H.
  • L is , anc [ R L i s hydrogen or -CO 2 H.
  • X 1 is -C(O)NR 1 -* or -NR 1 C(O)-*, indicating the attachment point to L 3 , and R 1 is H.
  • Z 1 is -CH 2 -
  • L 3 comprises (CH 2 CH 2 0) 2.2 o. In some embodiments, L 3 is (CH 2 CH 2 O)m(CH 2 ) w , wherein m and w are each independently an integer between 0 and 10 (inclusive), and at least one of m and w is not 0.
  • the metal complex comprises a metal selected from the group consisting of Bi, Pb, Y, Mn, Cr, Fe, Co, Zn, Ni, Tc, In, Ga, Cu, Re, a lanthanide, and an actinide.
  • the metal complex comprises a radionuclide selected from the group consisting of 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y, 87 Y, 89 Zr, 90 Y, 97 RU, "TC, " m Tc, 105 Rh, 109 Pd, m In, 117m Sn, 149 Pm, 149 Tb, 153 Sm, 166 Ho, 177 LU, 186 Re, 188 Re, 198 Au, 199 Au, 2O1 T1, 203 Pb, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, and 229 Th.
  • a radionuclide selected from the group consisting of 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga,
  • variable A is a metal complex of a chelating moiety.
  • the metal complex comprises a radionuclide.
  • the radionuclide is an alpha emitter, e.g., an alpha emitter selected from the group consisting of Astatine-211 ( 211 At), Bismuth-212 ( 212 Bi), Bismuth-213 ( 213 Bi), Actinium-225 ( 225 Ac), Radium-223 ( 223 Ra), Lead-212 ( 212 Pb), Thorium-227 ( 227 Th), and Terbium- 149 ( 149 Tb), or a progeny thereof.
  • the radionuclide is 68 Ga, in In, 177 Lu, or 225 Ac.
  • the radionuclide is 225 Ac or a progeny thereof.
  • compounds of Formula I comprise one of the following structures, or a metal complex thereof: [0018] In some embodiments, the compound or a pharmaceutically acceptable salt thereof comprises the following structure, or a metal complex thereof:
  • variable A is a metal complex of a chelating moiety, and the metal complex comprises a radionuclide.
  • the radionuclide is 68 Ga, in In, 177 Lu, or 225 Ac. In certain embodiments, the radionuclide is 225 Ac.
  • the radionuclide is an alpha emitter selected from the group consisting of Astatine-211 ( 211 At), Bismuth-212 ( 212 Bi), Bismuth-213 ( 213 Bi), Actinium-225 ( 225 AC), Radium-223 ( 223 Ra), Lead-212 ( 212 Pb), Thorium-227 ( 227 Th), and Terbium-149 ( 149 Tb), or a progeny thereof.
  • the alpha emitter is 225 Ac or a progeny thereof.
  • the first antigen binding domain comprises: i. a heavy chain variable (VH) region comprising the following complementarity determining regions (CDRs):
  • HCDR1 having the amino acid sequence of SEQ ID NO: 1
  • HCDR2 having the amino acid sequence of SEQ ID NO: 2
  • HCDR3 having the amino acid sequence of SEQ ID NO: 3
  • VL light chain variable
  • LCDR1 having the amino acid sequence of SEQ ID NO: 4
  • LCDR2 having the amino acid sequence of SEQ ID NO: 5
  • LCDR3 having the amino acid sequence of SEQ ID NO: 6.
  • the first antigen binding domain comprises: a. a VH region comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15; and b. a VL region comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16.
  • the second antigen binding domain comprises: i. a VH region comprising the following CDRs:
  • HCDR1 having the amino acid sequence of SEQ ID NO: 17
  • HCDR2 having the amino acid sequence of SEQ ID NO: 18
  • HCDR3 having the amino acid sequence of SEQ ID NO: 19, or a variant thereof in which one or two or three amino acids in one or more of HCDR1, HCDR2, and HCDR3 are substituted with another amino acid; and ii. a VL region comprising the following CDRs:
  • LCDR1 having the amino acid sequence of SEQ ID NO: 20
  • LCDR3 having the amino acid sequence of SEQ ID NO: 22, or a variant thereof in which one or two or three amino acids in one or more of LCDR1, LCDR2, and LCDR3 are substituted with another amino acid.
  • the second antigen binding domain comprises: i. a VH region comprising the following CDRs:
  • HCDR1 having the amino acid sequence of SEQ ID NO: 17
  • HCDR2 having the amino acid sequence of SEQ ID NO: 18
  • HCDR3 having the amino acid sequence of SEQ ID NO: 19; and ii. a VL region comprising the following CDRs:
  • LCDR1 having the amino acid sequence of SEQ ID NO: 20
  • LCDR3 having the amino acid sequence of SEQ ID NO: 22.
  • the second antigen binding domain comprises: a. a VH region comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 31; and b. a VL region comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 32.
  • the antibody or antigen-binding fragment thereof comprises: a. a first antigen-binding domain that is capable of binding epidermal growth factor receptor (EGFR), comprising: i. a heavy chain variable (VH) region comprising the following complementarity determining regions (CDRs):
  • EGFR epidermal growth factor receptor
  • VH heavy chain variable region comprising the following complementarity determining regions
  • HCDR1 having the amino acid sequence of SEQ ID NO: 1
  • HCDR2 having the amino acid sequence of SEQ ID NO: 2
  • HCDR3 having the amino acid sequence of SEQ ID NO: 3
  • VL light chain variable
  • LCDR1 having the amino acid sequence of SEQ ID NO: 4
  • LCDR2 having the amino acid sequence of SEQ ID NO: 5
  • LCDR3 having the amino acid sequence of SEQ ID NO: 6
  • a second antigen-binding domain that is capable of binding cMET, comprising: i. a VH region comprising the following CDRs:
  • HCDR1 having the amino acid sequence of SEQ ID NO: 17
  • HCDR2 having the amino acid sequence of SEQ ID NO: 18
  • HCDR3 having the amino acid sequence of SEQ ID NO: 19
  • CDRs ii. a VL region comprising the following CDRs:
  • LCDR1 having the amino acid sequence of SEQ ID NO: 20
  • LCDR2 having the amino acid sequence of SEQ ID NO: 21
  • LCDR3 having the amino acid sequence of SEQ ID NO: 22.
  • the antibody or antigen-binding fragment thereof comprises: a. a first heavy chain, wherein the first heavy chain comprises the VH region of the first antigen-binding domain, and a first heavy chain constant (CH) region or a fragment thereof; b. a first light chain, wherein the first light chain comprises the VL region of the first antigen-binding domain, and a first light chain constant (CL) region or a fragment thereof; c. a second heavy chain, wherein the second heavy chain comprises the VH region of the second antigen-binding domain, and a second heavy chain constant (CH) region or a fragment thereof; and d. a second light chain, wherein the second light chain comprises the VL region of the second antigen-binding domain, and a second light chain constant (CL) region or a fragment thereof.
  • a first heavy chain wherein the first heavy chain comprises the VH region of the first antigen-binding domain, and a first heavy chain constant (CH) region or a fragment thereof
  • the first and second CH region each comprise an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 33.
  • the first and second heavy chain form a heterodimer, optionally wherein one of the first and second heavy chains comprises a cysteine (C) residue at position 354 and a tryptophan (W) residue at position 366 and the other heavy chain comprises a cysteine (C) residue at position 349, a valine (V) residue at position 407, a serine (S) at position 366 and an alanine (A) at position 368, wherein the numbering of the constant region is as per the EU index.
  • C cysteine
  • W tryptophan residue
  • the antibody or antigen-binding fragment thereof comprises: a. a modified CH region, wherein the modified CH region comprises a substitution of a native non-cysteine amino acid to a cysteine amino acid; and b. a modified corresponding CL region, wherein the modified CL comprises a substitution of a native non-cysteine amino acid to a cysteine amino acid, wherein either: i. the first heavy chain comprises the modified CH region and the first light chain comprises the modified corresponding CL region; or ii. the second heavy chain comprises the modified CH region and the second light chain comprises the modified corresponding CL region, and wherein the substituted cysteine of the modified CH region and the substituted cysteine of the modified corresponding light chain can form a disulfide bond.
  • the modified CH region comprises a substitution of a native non-cysteine amino acid to a cysteine amino acid at position 126; and the modified corresponding CL region comprises a substitution of a native non-cysteine amino acid to a cysteine amino acid at position 121, wherein the numbering of the constant region is as per the EU index.
  • the first and/or second CH region comprise a mutation to reduce or abrogate binding of the antibody or antigen-binding fragment thereof to one of more Fey receptors.
  • the first and/or second CH region comprise a phenylalanine at position 234, glutamic acid at position 235, and serine at position 331, wherein the numbering of the constant region is as per the EU index.
  • the compound of Formula I features that: a. the first CH region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 39; b. the second CH region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 40, c.
  • the first CL region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 41; and d.
  • the second CL region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 34.
  • the antibody or antigen-binding fragment thereof comprises: a. a first heavy chain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 35; b. a second heavy chain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 36; c.
  • a first light chain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 37; and d. a second light chain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 38.
  • the compound of Formula I features that: a. the first heavy chain comprises an amino acid sequence having the sequence set forth in SEQ ID NO: 35; b. the second heavy chain comprises an amino acid sequence having the sequence set forth in SEQ ID NO: 36; c. the first light chain comprises an amino acid sequence having the sequence set forth in SEQ ID NO: 37; and d. the second light chain comprises an amino acid sequence having the sequence set forth in SEQ ID NO: 38.
  • the compound of Formula I features that: a. the first antigen-binding domain that is capable of binding EGFR is capable of binding cynomologus EGFR; b. the first antigen-binding domain that is capable of binding EGFR is capable of binding mouse EGFR; c. the second antigen-binding domain that is capable of binding cMET is capable of binding cynomologus cMET; d. the first antigen-binding domain is specific for EGFR; e. the second antigen-binding domain is specific for cMET; f. the antibody or antigen-binding fragment thereof is capable of concurrently engaging EGFR and cMET; g.
  • the antibody or antigen-binding fragment thereof is capable of being internalised into a cell; h. the antibody or antigen-binding fragment thereof has cytotoxic activity when measured in an in vitro cell viability assay; and/or i. the antibody or antigen-binding fragment thereof is capable of blocking ligand dependent signalling of EGFR and/or cMET.
  • the compound of Formula I features that the first antigenbinding domain is capable of binding human EGFR with an affinity having a Kd that is: a. between 10 and 100 nM; b. between 20 and 80 nM; c. between 30 and 75 nM; or d. between 35 and 50 nM.
  • the compound of Formula I features that the second antigenbinding domain is capable of binding human cMET with an affinity having a Kd that is: a. lower than 10 nM; or b. lower than 5 nM.
  • the compound of Formula I features that the first antigenbinding domain is capable of binding human EGFR with an affinity that is lower than the affinity that an antigen-binding domain comprising the variable heavy region sequence and variable light region sequence of antibody QD6, the sequences set forth in SEQ ID NOs: 47 and 48, respectively.
  • the binding affinity described above is measured by surface plasmon resonance.
  • the compound of Formula I comprises the following structure: wherein is an antibody or an antigen-binding fragment thereof that is capable of specifically binding both EGFR and cMET (e.g., EGFR-cMET monoclonal bispecific antibody RAA22/B09 DuetMab described below).
  • the antibody or an antigen-binding fragment thereof is linked to A-L 1 - ⁇ 2 )]!- via the side-chain amino group of a lysine residue.
  • the present disclosure also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one of the compounds described above and a pharmaceutically acceptable carrier, diluent, or excipient.
  • a method of treating cancer comprising administering to a subject (e.g., a human) in need thereof a therapeutically effective amount a compound described above or a respective composition thereof.
  • the cancer is a solid tumor cancer selected from the group consisting of adrenocortical carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial adenocarcinoma, Ewing’s sarcoma, gallbladder carcinoma, glioma, head and neck cancer (e.g., head and neck squamous cell carcinomas or HNSCC), liver cancer, lung cancer (e.g., non-small cell lung cancer or NSCLC), neuroblastoma, neuroendocrine cancer, ovarian cancer, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma or PDAC), prostate cancer, gastric cancer, renal cell carcinoma, salivary adenoid cystic cancer, spermatocytic seminoma, and uveal melanoma.
  • adrenocortical carcinoma bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial adenocarcinoma, Ewing’
  • the cancer is lung cancer, colorectal cancer, pancreatic cancer, or head and neck cancer.
  • the method of treatment of this invention further comprises administering to a subject (e.g., a human) in need thereof an antiproliferative agent, radiation sensitizer, an immunoregulatory or immunomodulatory agent.
  • the present disclosure further covers use of a compound or the pharmaceutical composition described above in the manufacture of a medicament for the treatment of cancer.
  • FIGs. 1A and IB are graphical depiction of RAA22/B09-57 and QD6/B09-57 DuetMabs, respectively. Shown are the Fabs of anti-EGFR RAA22 and QD6, Fab of anti- cMET B09-57 and Hole and Knob heavy chains. The structural rendering is a composite of individual domain structures.
  • FIG. 3A shows ELISA results showing EGFR and c-Met species cross reactivity. The high affinity monospecific EGFR IgG, QD6, as well as the monovalent bispecific EGFR/cMET DuetMAb, QD6/B09, bound to human, cynomolgus monkey, and mouse EGFR.
  • 3B shows ELISA results showing EGFR and c-Met family specificity. None of the antibodies tested showed any appreciable binding to any of the EGFR HER family proteins (HER2, HER3, or HER4) or any of the c-Met family members (Ron (CD 136) or Semaphorin 3a).
  • FIG. 4 shows internalization of RAA22/B09 bispecific mAb and trafficking to acidified intracellular compartments was visualized using antibodies labeled with pHAb pH sensitive dye (Promega).
  • Control antibodies included R347 isotype control and the monovalent bispecific control antibodies anti-EGFR RAA22/R347 and anti-cMET B09/R347.
  • the pHAb labelled antibodies were incubated with NCI-H1975 lung cancer cells at a concentration of 1.25 pg/mL in a humidified incubator at 37°C and 5% CO2.
  • Fluorescent images were captured at the indicated time points on an Operetta High Content Imaging system using the Cy3 filter. Increased cellular fluorescence intensity over time was deemed evidence of internalization and trafficking to acidic intracellular compartments as measured by the pH sensitive fluor.
  • FIG. 5 shows internalization of RAA22/B09 bispecific mAb and trafficking to acidified intracellular compartments was visualized using antibodies labeled with pHAb pH sensitive dye, but the cells were treated with antibodies at the lower concentration of 0.625 pg/mL.
  • FIG. 6A shows kinetics of QD6/B09 and RAA22/B09 monoclonal antibody (mAb) internalization in H1975 cells, (a) Image overlays of cells labeled with CellTracker Blue CMAC for cytoplasm (blue) and with 2.5 pg/mL of QD6/B09-AlexaFluor647 (magenta, top panel) or 2.5 pg/mL of RAA22/B09AlexaFluor-647 (magenta, bottom panel) at the start of internalization and 1 hr after. Cells were labeled with CellTracker Blue CMAC, then bound with mAbs-AlexaFuor6457 at 2-8°C and subjected to internalization conditions: (37°C, 70% humidity and 5% CO2).
  • FIG. 6B shows kinetics of QD6/B09 and RAA22/B09 monoclonal antibody (mAb) internalization in H1975 cells.
  • Time course of mAb-AlexaFluor647 internalization determined by quantitative analysis of kinetic images using the algorithm (Material and Methods). Kinetic images taken at 5-minute intervals were processed using the algorithm (Vainshtein, 2015) to determine antibody accumulation in cytoplasm.
  • Antibody signals in cytoplasm normalized to antibody fluorescence in the cell (fraction in cytoplasm) for QD6/B09-AlexaFluor647 (red) versus RAA22/B09-AlexaFluor647 (blue) are shown for one of the three independent experiments.
  • FIG. 7A shows internalization profiles of QD6/B09 DuetMab and its respective single-arm control antibodies. Internalization profiles are displayed via time course of the respective membrane and cytoplasm signals for each construct. QD6/B09 set was acquired using an Opera confocal fluorescence microscope.
  • FIG. 7B shows internalization profiles of RAA22/B09 DuetMab and its respective single-arm control antibodies. Internalization profiles are displayed via time course of the respective membrane and cytoplasm signals for each construct. The set was acquired using a Zeiss spinning-disc confocal fluorescence microscope. Identical profiles for QD6/B09 and QD6/IgG indicate internalization mode driven by EGFR-arm of QD6/B09 DuetMab, whereas RAA22/B09 DuetMab requires engagement of both EGFR and c-MET arms for efficient internalization.
  • FIG. 8A shows internalization profile of RAA22/B09 in cells expressing moderate and high target c-MET and EGFR cell surface receptors. Shown are membrane, cytoplasm and total signals for RAA22/B09-AF647 in H1975 cells. One representative experiment of 2 is shown. H1975 cells show concurrent drop in total and membrane intensities indicating dissociation of antibody from the cell surface.
  • FIG. 8B is equivalent to FIG. 8A but in HCC827 cells.
  • HCC827 cells have stable total signal over experimental time course. Decrease of membrane signal is derived antibody internalization.
  • FIG. 9A shows internalization of RAA22/B09 single arm control antibodies in HCC827 cells. Intensity profiles of the RAA22/IgG single arm is about 10-fold lower than RAA22/B09 due to weaker binding to EGFR through single arm binding
  • FIG. 9B shows that B09/IgG single arm dissociates from cell membrane as signaled by simultaneous drops in total and membrane signals over time.
  • FIG. 10A is a schematic depicting the general structure of bifunctional chelate comprising a chelate, a linker, and a cross-linking group.
  • FIG. 10B is a schematic depicting the general structure of a bifunctional conjugate comprising a chelate, a linker, and a targeting moiety.
  • FIG. 11 is a schematic depicting the synthesis of the bifunctional chelate, 4- ⁇ [ 11 - oxo-l l-(2,3,5,6-tetrafluorophenoxy)undecyl]carbamoyl ⁇ -2-[4,7,10-tris(carboxymethyl)- l,4,7,10-tetraazacyclododecan-l-yl]butanoic acid (Compound B). Synthesis of Compound B is described in EXAMPLE 6.
  • FIG. 12 is a schematic depicting the synthesis of the bifunctional chelate, 4- ⁇ [2-(2- ⁇ 2-[3-oxo-3-(2,3,5,6-tetrafluorophenoxy)propoxy]ethoxy ⁇ ethoxy)ethyl]carbamoyl ⁇ -2- [4,7, 10-tris(carboxymethyl)- 1 ,4,7, 10-tetraazacyclododecan- 1 -yl]butanoic acid (Compound C). Synthesis of Compound C is described in EXAMPLE 7.
  • FIG. 13 is a schematic depicting the conjugation and radiolabeling for synthesis of [ 177 Lu]-Compound C-anti-EGFR-cMET conjugate (e.g., Compound E and Compound F described below). See EXAMPLE 8.
  • Percentage injected dose per gram of tissue (% ID/g) is plotted on the x-axis and is shown for blood, bone, brain, heart, intestines, kidneys, lungs, liver, pancreas, spleen, stomach, skin, urine and bladder, and tumor at 4, 24, 48, 96, and 168 hours. See EXAMPLE 11.
  • Radioimmunoconjugates are designed to target a protein or receptor that is upregulated in a disease state to deliver a radioactive payload to damage and kill cells of interest (radioimmunotherapy).
  • Delivering a radioactive payload results in targeted alpha, beta, gamma particle or Auger electron emission that can cause direct effects to DNA (such as single or double stranded DNA breaks) or indirect effects such as by-stander or crossfire effects.
  • Radioimmunoconjugates typically contain a biological targeting moiety (e.g., an antibody or antigen binding fragment thereof that is capable of specifically binding to both EGFR and cMET), a radionuclide (e.g., an alpha or beta emitter), and a molecule that links the two. Conjugates are formed when a bifunctional chelate is appended to the biological targeting moiety so that structural alterations are minimal while maintaining target affinity. Once radiolabelled, the final radioimmunoconjugate is formed.
  • a biological targeting moiety e.g., an antibody or antigen binding fragment thereof that is capable of specifically binding to both EGFR and cMET
  • a radionuclide e.g., an alpha or beta emitter
  • Bifunctional chelates structurally contain a chelate, a linker, and a cross-linking group (FIG. 10A).
  • a linker When developing new bifunctional chelates, most efforts focus on the chelating portion of the molecule.
  • bifunctional chelates have been described with various cyclic and acyclic structures conjugated to a targeted moiety. [Bioconjugate Chem. 2000, 11, 510-519; Bioconjugate Chem. 2012, 23, 1029-1039; Mol Imaging Biol. 2011, 13, 215-221, Bioconjugate Chem. 2002, 13, 110-115.]
  • Radioimmunoconjugates do not need to block a receptor, as needed with a therapeutic antibody, or release the cytotoxic payload intracellularly, as required by an antibody drug conjugate (“ADC”), to have therapeutic efficacy.
  • ADC antibody drug conjugate
  • the emission of the toxic particle is an event that occurs as a result of first-order (radioactive) decay and can occur at random anywhere inside the body after administration. Once the emission occurs, damage could occur to surrounding cells within the range of the emission leading to the potential of off-target toxicity. Therefore, limiting exposure of these emissions to normal tissue is the key to developing new therapeutic radioimmunoconjugates.
  • One potential method for reducing off-target exposure is to remove the radioactivity more effectively from the body (e.g., from normal tissue in the body).
  • One mechanism is to increase the rate of clearance of the biological targeting agent. This approach likely requires identifying ways to shorten the half-life of the biological targeting agent, which is not well described for biological targeting agents. Regardless of the mechanism, increasing drug clearance will also negatively impact the pharmacodynamics/efficacy in that the more rapid removal of drug from the body will lower the effective concentration at the site of action, which, in turn, would require a higher total dose and would not achieve the desired results of reducing total radioactive dose to normal tissue.
  • cleavable linkers as those by which the bifunctional chelate attaches to the biologic targeting agent through a reduced cysteine, whereas others have described the use of enzyme-cleavable systems that require the co-administration of the radioimmunoconjugate with a cleaving agent/enzyme to release [Mol Cancer Ther. 2013, 12(11), 2472-2482; Methods Mol Biol. 2009, 539, 191-211; Bioconjug Chem.
  • the present disclosure provides, among other things, compounds, e.g., radioimmunoconjugates, that are more effectively eliminated from the body after catabolism and/or metabolism, thereby more effectively eliminating radioactivity from the body while maintaining therapeutic efficacy.
  • compounds e.g., radioimmunoconjugates
  • Disclosed immunoconjugates may, in some embodiments, achieve a reduction of total body radioactivity, for example, by increasing the extent of excretion of the catabolic/metabolic products while maintaining the pharmacokinetics of the intact molecule when compared to known bifunctional chelates. In some embodiments, this reduction in radioactivity results from the clearance of catabolic/metabolic by-products without impacting other in vitro and in vivo properties such as binding specificity (in vitro binding), cellular retention, and tumor uptake in vivo. Thus, in some embodiments, provided compounds achieve reduced radioactivity in the human body while maintaining on-target activity.
  • bind or “binding” of a targeting moiety means an at least temporary interaction or association with or to a target molecule, e.g., human EGFR-cMET, as described herein.
  • a target molecule e.g., human EGFR-cMET
  • a “crosslinking group” is a reactive group that is capable of joining two or more molecules, e.g., joining a bifunctional chelate and a targeting moiety, by a covalent bond.
  • bifunctional conjugate refers to a compound that comprises a chelate or metal complex thereof, a linker, and a targeting moiety, e.g., an antibody or antigen-binding fragment thereof. See, e.g., FIG. 10B.
  • cancer refers to any cancer caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas.
  • a cancer of the present disclosure comprises cells (e.g., tumor cells) expressing EGFR and cMET, such as, but not limited to, lung cancer, colorectal cancer, pancreatic cancer, or head and neck cancer.
  • chelate refers to an organic compound or portion thereof that can be bonded to a central metal or radiometal atom at two or more points.
  • conjugate refers to a molecule that contains a chelating group or metal complex thereof, a linker group, and which optionally contains a targeting moiety, e.g., an antibody or antigen-binding fragment thereof.
  • the phrase “constant region,” when used in reference to an antibody or a fragment thereof is intended to encompass both wild type constant regions and variants (e.g., constant regions having at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% amino acid sequence identity with a reference sequence for a wild-type constant region.
  • the term “compound,” is meant to include all stereoisomers, geometric isomers, and tautomers of the structures depicted.
  • the compounds recited or described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • Compounds discussed in the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis.
  • detection agent refers to a molecule or atom which is useful in diagnosing a disease by locating the cells containing the antigen.
  • detection agents include, but are not limited to, radioisotopes and radionuclides, dyes (such as with the biotin-streptavidin complex), contrast agents, luminescent agents (e.g., fluorescein isothiocyanate or FITC, rhodamine, lanthanide phosphors, cyanine, and near IR dyes), and magnetic agents, such as gadolinium chelates.
  • the term “radionuclide,” refers to an atom capable of undergoing radioactive decay (e.g., 3 H, 14 C, 15 N, 18 F, 35 S, 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 75 Br 76 Br 77 Br 89 Zr 86 Y 87 Y 90 Y 97 Ru "Tc " m Tc 105 Rh 109 Pd ni In 123 I 124 I 125 I 131 I 149 Pm, 149 Tb, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 198 Au, 199 Au, 203 Pb, 211 At, 212 Pb , 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, 229 Th, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 117m Sn, 2O1 T1).
  • radioactive decay e.g., 3 H, 14 C, 15 N, 18
  • radioactive nuclide may also be used to describe a radionuclide.
  • Radionuclides may be used as detection agents, as described herein.
  • the radionuclide may be used as therapeutic agents, e.g., an alpha-emitting radionuclide.
  • an “effective amount” of an agent e.g., any of the foregoing conjugates, as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied.
  • an “effective amount” may be an amount sufficient to cure or at least partially arrest the symptoms of the disorder and its complications, and/or to substantially improve at least one symptom associated with the disease or a medical condition.
  • an “effective amount” in the context of the present disclosure is an amount of a compound (e.g., radioimmunoconjugate) disclosed herein, e.g., an Ac-225-radioimmunoconjugate, that produces at least some measurable therapeutic response or desired effect in some fraction of the patient to whom it is administered.
  • a compound e.g., radioimmunoconjugate
  • an agent or compound that decreases, prevents, delays, suppresses, or arrests any symptom of the disease or condition would be therapeutically effective.
  • a therapeutically effective amount of an agent or compound is not required to cure a disease or condition but may, for example, provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered, or prevented, such that the disease or condition symptoms are ameliorated, or such that the term of the disease or condition is changed. For example, the disease or condition may become less severe and/or recovery is accelerated in an individual.
  • An effective amount may be administered by administering a single dose or multiple (e.g., at least two, at least three, at least four, at least five, or at least six) doses.
  • immunoconjugate refers to a conjugate that includes a targeting moiety, such as an antibody (or antigen-binding fragment thereof), nanobody, affibody, or a consensus sequence from Fibronectin type III domain.
  • the immunoconjugate comprises an average of at least 0.10 conjugates per targeting moiety (e.g., an average of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, or 8 conjugates per targeting moiety).
  • radioconjugate refers to any conjugate that includes a radioisotope or radionuclide, such as any of the radioisotopes or radionuclides described herein.
  • radioimmunoconjugate refers to any immunoconjugate that includes a radioisotope or radionuclide, such as any of the radioisotopes or radionuclides described herein.
  • a radioimmunoconjugate provided in the present disclosure typically refers to a bifunctional conjugate that comprises a metal complex formed from a radioisotope or radionuclide.
  • radioimmunotherapy refers a method of using a radioimmunoconjugate to produce a therapeutic effect.
  • radioimmunotherapy may include administration of a radioimmunoconjugate to a subject in need thereof, wherein administration of the radioimmunoconjugate produces a therapeutic effect in the subject.
  • radioimmunotherapy may include administration of a radioimmunoconjugate to a cell, wherein administration of the radioimmunoconjugate kills the cell.
  • radioimmunotherapy involves the selective killing of a cell, in some embodiments the cell is a cancer cell in a subject having cancer.
  • composition represents a composition containing a radioimunoconjugate described herein formulated with a pharmaceutically acceptable excipient.
  • the pharmaceutical composition is manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal.
  • compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other formulation described herein.
  • unit dosage form e.g., a tablet, capsule, caplet, gelcap, or syrup
  • topical administration e.g., as a cream, gel, lotion, or ointment
  • intravenous administration e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use
  • a “pharmaceutically acceptable excipient,” as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being nontoxic and noninflammatory in a patient.
  • Excipients may include, for example: anti adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, radioprotectants, sorbents, suspending or dispersing agents, sweeteners, or waters of hydration.
  • excipients include, but are not limited to: ascorbic acid, histidine, phosphate buffer, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid,
  • salts represent those salts of the compounds described here that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, or allergic response.
  • Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. Salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable organic acid.
  • the compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts.
  • These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases.
  • the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases.
  • Suitable pharmaceutically acceptable acids and bases are well-known in the art, such as hydrochloric, sulphuric, hydrobromic, acetic, lactic, citric, or tartaric acids for forming acid addition salts, and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines for forming basic salts. Methods for preparation of the appropriate salts are well-established in the art.
  • Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemi sulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.
  • polypeptide refers to a string of at least two amino acids attached to one another by a peptide bond.
  • a polypeptide may include at least 3-5 amino acids, each of which is attached to others by way of at least one peptide bond.
  • polypeptides can include one or more “non-natural” amino acids or other entities that nonetheless are capable of integrating into a polypeptide chain.
  • a polypeptide may be glycosylated, e.g., a polypeptide may contain one or more covalently linked sugar moieties.
  • a single “polypeptide” (e.g., an antibody polypeptide) may comprise two or more individual polypeptide chains, which may in some cases be linked to one another, for example by one or more disulfide bonds or other means.
  • subject is meant a human or non-human animal (e.g., a mammal).
  • substantial identity or “substantially identical” is meant a polypeptide sequence that has the same polypeptide sequence, respectively, as a reference sequence, or has a specified percentage of amino acid residues, respectively, that are the same at the corresponding location within a reference sequence when the two sequences are optimally aligned.
  • an amino acid sequence that is “substantially identical” to a reference sequence has at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the reference amino acid sequence.
  • the length of comparison sequences will generally be at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75, 90, 100, 150, 200, 250, 300, or 350 contiguous amino acids (e.g., a full- length sequence).
  • Sequence identity may be measured using sequence analysis software on the default setting (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software may match similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications.
  • beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilized (i.e., not worsening) state of disease, disorder, or condition; preventing spread of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable.
  • “Palliating” a disease, disorder, or condition means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.
  • EGFR-cMET targeting moiety refers to a targeting moiety (e.g., an antibody or antigen-binding fragment thereof) that is capable of binding to both EGFR and cMET, e.g., anti -EGFR-cMET antibody.
  • fragment when used to refer to an EGFR or cMET fragment, refers to N-terminally and/or C-terminally truncated EGFR or cMET or protein domains thereof. Unless otherwise noted, fragments of EGFR or cMET used in accordance with embodiments described herein retain the capability of the full-length EGFR or cMET to be recognized and/or bound by an EGFR-cMET -targeting moiety as described in the present disclosure.
  • antibody refers to a polypeptide whose amino acid sequence includes immunoglobulins and fragments thereof which specifically bind to a designated antigen, or fragments thereof.
  • Antibodies in accordance with the present invention may be of any type (e.g., IgA, IgD, IgE, IgG, or IgM) or subtype (e.g., IgAl, IgA2, IgGl, IgG2, IgG3, or IgG4).
  • a characteristic sequence or portion of an antibody may include amino acids found in one or more regions of an antibody (e.g., variable region, hypervariable region, constant region, heavy chain, light chain, and combinations thereof).
  • a characteristic sequence or portion of an antibody may include one or more polypeptide chains, and may include sequence elements found in the same polypeptide chain or in different polypeptide chains.
  • antigen-binding fragment refers to a portion of an antibody that retains the specificity of the binding characteristics of the parent antibody.
  • Antibodies or antigen-binding fragments thereof of the present disclosure may be isolated and/or substantially purified.
  • this disclosure provides compounds, e.g., immunoconjugates or radioimmunoconjugates, comprising the following structure, or pharmaceutically acceptable salts thereof
  • A is a chelating moiety or a metal complex thereof
  • B is an antibody or antigen-binding fragment thereof that is capable of binding to both EGFR and cMET, wherein the antibody or antigen-binding fragment thereof is featured as disclosed herein;
  • n is an integer between 1 and 5 (inclusive);
  • L 2 each independently has the structure of Formula II:
  • Formula II wherein -NR 1 C(O)O-*, -NR 1 C(O)NR 1 -*, -CH 2 -Ph-C(O)NR 1 -*, -NR 1 C(O)-Ph-CH 2 -*, -CH 2 -Ph- NH-C(S)NR 1 -*, -NR ⁇ Sj-NH-Ph-CHi-*, -O-*, or -NR 1 -*; wherein indicates the attachment point to L 3 , and R 1 is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, or optionally substituted aryl or heteroaryl;
  • L 3 is optionally substituted C1-C50 alkyl or optionally substituted C1-C50 heteroalkyl
  • Z 1 is-CH 2 -#, -C(O)- #, -C(S)- #, -OC(O)-#, -C(O)O-#, -NR 2 C(O)-#, - C(O)NR 2 -#, or -NR 2 -#, wherein “#” indicates the attachment point to B, and R 2 is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • Typical substituents of alkyl, heteroalkyl, aryl, or heteroaryl include, but are not limited to halo (e.g., F, Cl, Br, I), OH, CN, nitro, amino, Ci-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C3-8 cycloalkyl, Ci-6 heteroalkyl, Ci-6 heterocycloalkyl, haloalkyl (e.g., CF3), alkoxy (e.g., OCH3), alkylamino (e.g., NH 2 CH3), sulfonyl, aryl, and heteroaryl.
  • halo e.g., F, Cl, Br, I
  • OH e.g., OH, CN
  • nitro amino
  • Ci-6 alkyl C 2 -6 alkenyl, C 2 -6 alkynyl, C3-8 cycloalkyl
  • Ci-6 heteroalkyl Ci
  • the compound e.g., immunoconjugate or radioimmunoconjugate
  • the compound has or comprises the structure shown below, or a metal complex thereof: wherein B is an EGFR-cMET antibody or antigen-binding fragment thereof as disclosed herein.
  • the compound of Formula I comprises one of the following structures, or a metal complex thereof:
  • provided compounds are capable of binding to different cell lines with varying expression levels of EGFR and cMET with a Kd value of at most about 25 nM, at most about 20 nM, at most about 15 nM, at most about 12.5 nM, at most about 10 nM, at most about 7.5 nM, at most about 7 nM, at most about 6.5 nM, at most about 6 nM, at most about 5 nM, at most about 4 nM, at most about 3.5 nM, at most about 3 nM, or at most about 2.5 nM.
  • provided compounds are capable of binding to different cell lines with varying expression levels of EGFR and cMET with a Kd value of about 15 nM, about 12.5 nM, about 10 nM, about 7.5 nM, about 7 nM, about 6.5 nM, about 6 nM, about 5 nM, about 4 mM, about 3.5 nM, about 3 nM, or about 2.5 nM.
  • the compound comprises a chelating moiety or a metal complex thereof, which metal complex may comprise a radionuclide.
  • the average ratio or median ratio of the chelating moiety to the EGFR-cMET targeting moiety is eight or less, seven or less, six or less, five or less, four or less, three or less, two or less, or about one.
  • the average ratio or median ratio of the chelating moiety to the EGFR-cMET targeting moiety e.g., EGFR-cMET antibody
  • the average ratio or median ratio of the chelating moiety to the EGFR-cMET targeting moiety is about one.
  • the proportion of radiation (of the total amount of radiation that is administered) that is excreted by the intestinal route, the renal route, or both is greater than the proportion of radiation excreted by a comparable mammal that has been administered a reference radioimmunoconjugate.
  • reference immunoconjugate it is meant a known radioimmunoconjugate that differs from a radioimmunoconjugate described herein at least by (1) having a different linker; (2) having a targeting moiety of a different size and/or (3) lacking a targeting moiety.
  • the reference radioimmunoconjugate is selected from the group consisting of [ 90 Y]-ibritumomab tiuxetan (Zevalin ( 90 Y)) and [ m In]- ibritumomab tiuxetan (Zevalin ( m In)).
  • the proportion of radiation excreted by a given route or set of routes is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% greater than the proportion of radiation excreted by the same route(s) by a comparable mammal that has been administered a reference radioimmunoconjugate.
  • the proportion of radiation excreted is at least 1.5-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than proportion of radiation excreted by a comparable mammal that has been administered a reference radioimmunoconjugate.
  • the extent of excretion can be measured by methods known in the art, e.g., by measuring radioactivity in urine and/or feces and/or by measuring total body radioactivity over a period time. See also, e.g., International Patent Publication WO 2018/024869.
  • the extent of excretion is measured at a time period of at least or about 12 hours after administration, at least or about 24 hours after administration, at least or about 2 days after administration, at least or about 3 days after administration, at least or about 4 days after administration, at least or about 5 days after administration, at least or about 6 days after administration, or at least or about 7 days, after administration.
  • the compound e.g., immunoconjugate or radioimmunoconjugate
  • the compound exhibits decreased off-target binding effects (e.g., toxicides) as compared to a reference compound (e.g., reference conjugate, e.g., a reference immunoconjugate such as a reference radioimmunoconjugate).
  • this decreased off-target binding effect is a feature of a compound (e.g., immunoconjugate or radioimmunoconjugate) that also exhibits a greater excretion rate as described herein.
  • Targeting moieties include any molecule or any part of a molecule that is capable of binding (e.g., capable of specifically binding, specifically binds to, etc.) to a given target, e.g., EGFR or cMET, or EGFR-cMET.
  • the targeting moiety comprises a protein or polypeptide.
  • the targeting moiety is selected from the group consisting of antibodies or antigen binding fragments thereof, nanobodies, affibodies, and consensus sequences from Fibronectin type III domains (e.g., Centyrins or Adnectins).
  • a moiety is both a targeting and a therapeutic moiety, i.e., the moiety is capable of binding to a given target and also confers a therapeutic benefit.
  • the targeting moiety has a molecular weight of at least 50 kDa, at least 75 kDa, at least 100 kDa, at least 125 kDa, at least 150 kDa, at least 175 kDa, at least 200 kDa, at least 225 kDa, at least 250 kDa, at least 275 kDa, or at least 300 kDa.
  • the targeting moiety is capable of specifically binding to and inhibits both EGFR and cMET.
  • inhibits it is meant that the targeting moiety at least partially inhibits one or more functions of EGFR, cMET, or both.
  • the targeting moiety impairs signaling downstream of EGFR, cMET, or both, e.g., results in the suppressed growth of tumor cells with varying expression levels of EGFR and cMET.
  • Human EGFR also known as proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1 and EC 2.7.10.1
  • Human EGFR is the protein identified by UniProt P00533.
  • isoform 1 (UniProt: P00533-1, v2 (last sequence update: November 1, 1997)); isoform 2 (UniProt: P00533-2, vl), which comprises the substitutions F404L and L405S relative to isoform 1, and which lacks the amino acid sequence corresponding to positions 406 to 1210 of isoform 1; isoform 3 (UniProt: P00533-3, vl), which comprises substitutions at position 628 to 705 of isoform 1, and which lacks the amino acid sequence corresponding to positions 706 to 1210 of isoform 1; and isoform 4 (UniProt: P00533-4), which comprises the substitution C628S relative to isoform 1, and which lacks the amino acid sequence corresponding to positions 629 to 1210 of isoform 1.
  • EGFR is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family).
  • the receptor comprises a large extracellular region, a single spanning transmembrane domain, an intracellular juxtamembrane domain, a tyrosine kinase domain and a C-terminal regulatory region.
  • Binding of EGFR to a ligand induces receptor dimerization and autophosphorylation of several tyrosine residues (Y992, Y1045, Y1068, Y1148 and Y1173) in the C-terminal regulatory region of EGFR.
  • EGFR refers to EGFR from any species and includes EGFR isoforms, fragments, variants or homologues from any species.
  • Human cMET also known as Hepatocyte growth factor receptor (HGFR) or tyrosine-protein kinase Met
  • HGFR Hepatocyte growth factor receptor
  • Met tyrosine-protein kinase Met
  • isoform 1 UniProt: P08581-1, v4 (last sequence update: July 7, 2009)
  • isoform 2 UniProt: P08581-2
  • isoform 3 UniProt: P08581-3
  • Soluble met variant 4 in which the amino acid sequence corresponding to positions 755 to 764 of isoform 1 are substituted with “RHVNIALIQR” and which further lacks the amino acid sequence corresponding to positions 765 to 1390 of isoform 1.
  • cMET is a heterodimer made of an alpha chain (50 kDa) and a beta chain (145 kDa), which are disulphide linked.
  • cMET comprises a N-terminal Serna domain, which mediates binding to hepatocyte growth factor (HGF) and an intracellular kinase domain. Ligand binding at the cell surface induces autophosphorylation of cMET on its intracellular domain that provides docking sites for downstream signalling molecules and the activation of several signalling cascades.
  • HGF hepatocyte growth factor
  • cMET is expressed in normal tissues on the surface of epithelial cells. cMET overexpression is observed in many human tumors and cancers, which is frequently associated with a metastatic phenotype and poor prognosis. Examples of cancers where high levels of cMET expression has been observed includes non-small cell lung cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell carcinoma, breast cancer and esophageal -gastric cancer. In these cancers, co-expression of EGFR and cMET is often observed.
  • antibody describes an immunoglobulin whether natural or partly or wholly synthetically produced.
  • the antibody may be human or humanised.
  • the antibody is preferably a monoclonal antibody.
  • examples of antibodies are the immunoglobulin isotypes, such as immunoglobulin G (IgG), and their isotypic subclasses, such as IgGl, IgG2, IgG3 and IgG4, as well as fragments thereof.
  • antibody thus includes antibody fragments, as long as they display binding to the relevant target molecule(s).
  • antibody fragments include Fv, scFv, Fab, scFab, F(ab’)2, Fab2, diabodies, triabodies, scFv-Fc, minibodies and single domain antibodies (e.g., VhH), etc.).
  • antibody is thus equivalent to “antibody or fragment thereof’.
  • Antibodies and methods for their construction and use are well-known in the art and are described in, for example, Holliger & Hudson, Nature Biotechnology 23(9): 1126-1136 (2005). It is possible to take monoclonal and other antibodies and use techniques of recombinant DNA technology to produce other antibody or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing CDRs or variable regions of one antibody into a different antibody (EP-A-184187, GB 2188638 A and EP-A-239400).
  • antibodies can be prepared to most antigens.
  • the antigen-binding domain may be a part of an antibody (for example a Fab fragment) or a synthetic antibody fragment (for example a single chain Fv fragment (ScFv)).
  • Suitable monoclonal antibodies to selected antigens may be prepared by known techniques, for example those disclosed in "Monoclonal Antibodies: A manual of techniques ", H Zola (CRC Press, 1988) and in “Monoclonal Hybridoma Antibodies: Techniques and Applications ", J G R Hurrell (CRC Press, 1982). Chimaeric antibodies are discussed by Neuberger, 1988.
  • Antibodies according to the present disclosure comprise an antigen-binding domain.
  • An “antigen-binding domain” describes the part of a molecule that binds to all or part of the target antigen. Where an antigen is large, an antibody may only bind to a particular part of the antigen, which part is termed an epitope.
  • An antibody antigen-binding site may be provided by one or more antibody variable domains.
  • An antibody antigenbinding site preferably comprises a variable light (VL) region and variable heavy (VH) region. The VH and VL region of an antigen-binding domain together constitute the Fv region.
  • An antigen-binding domain generally comprises six complementarity-determining regions (CDRs); three in the VH region: HCDR1, HCDR2 and HCDR3, and three in the VL region: LCDR1, LCDR2, and LCDR3.
  • CDRs complementarity-determining regions
  • VH region and VL region comprise framework regions (FRs) either side of each CDR, which provide a scaffold for the CDRs.
  • FRs framework regions
  • VH regions comprise the following structure: N term-[HFRl]-[HCDRl]-[HFR2]-[HCDR2]- [HFR3]-[HCDR3]-[HFR4]-C term; and VL regions comprise the following structure: N term- [LFR1]-[LCDR1]-[LFR2]-[LCDR2]-[LFR3]-[LCDR3]-[LFR4]-C term.
  • Antibodies that comprise at least two antigen-binding domains, each of which being capable of binding to a different target may be termed “bispecific antibodies”.
  • antibodies that only bind a single target e.g., EGFR or cMET
  • monospecific antibodies antibodies that only bind a single target (e.g., EGFR or cMET) are termed “monospecific antibodies”.
  • compounds, (e.g., radioimmunoconjugates) comprising a bispecific antibody or antigen-binding fragment thereof comprising a first antigen binding domain that is capable of binding EGFR and a second antigen-binding domain that is capable of binding cMET.
  • the antigen-binding domain that is capable of binding EGFR comprises the CDRs of an antibody which is capable of binding to EGFR.
  • the antigenbinding domain is capable of binding EGFR additionally comprises the FRs of an antibody which is capable of binding to EGFR. That is, in some embodiments the antigen-binding domain that is capable of binding EGFR comprises the VH region and the VL region of an antibody which is capable of binding to EGFR.
  • the antigen-binding domain that is capable of binding EGFR comprises a VH region and a VL region which is, or which is derived from, the VH/VL region of an EGFR-binding antibody clone RAA22.
  • the antigen-binding domain that is capable of binding EGFR comprises the three HCDRs or three LCDRs, preferably the three VH CDRs and the three VL CDRs, of anti-EGFR antibody clone RAA22.
  • the VH and VL domain sequences of antibody RAA22 are described herein, and the three VH and three VL domain CDRs of said antibody may thus be determined from said sequences.
  • the antigen-binding domain that is capable of binding EGFR comprises a VH region according to (1):
  • VH region comprising the following CDRs:
  • HCDR1 having the amino acid sequence of SEQ ID NO: 1
  • HCDR2 having the amino acid sequence of SEQ ID NO: 2
  • HCDR3 having the amino acid sequence of SEQ ID NO: 3.
  • the antigen-binding domain that is capable of binding EGFR comprises a VH region according to (1), wherein the VH region additionally comprises the FRs according to (2) below:
  • HFR1 having the amino acid sequence of SEQ ID NO: 7
  • HFR2 having the amino acid sequence of SEQ ID NO: 8
  • HFR3 having the amino acid sequence of SEQ ID NO: 9
  • HFR4 having the amino acid sequence of SEQ ID NO: 10, or a variant thereof in which one or two or three amino acids in one or more of HFR1, HFR2, HFR3, or HFR4 are substituted with another amino acid.
  • the antigen-binding domain that is capable of binding EGFR comprises a VH region according to (3) below: (3) a VH region comprising the CDRs according to (1) and the FRs according to (2).
  • the antigen-binding domain that is capable of binding EGFR comprises a VH region according to (4):
  • VH region comprising an amino acid sequence having at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO: 15.
  • the antigen-binding domain that is capable of binding EGFR comprises a VL region according to (5) below:
  • VL region comprising the following CDRs:
  • LCDR1 having the amino acid sequence of SEQ ID NO: 4
  • LCDR2 having the amino acid sequence of SEQ ID NO: 5
  • LCDR3 having the amino acid sequence of SEQ ID NO: 6.
  • the antigen-binding domain that is capable of binding EGFR comprises a VL region according to (5) above, wherein the VL region additionally comprises the FRs according to (6) below:
  • LFR1 having the amino acid sequence of SEQ ID NO: 11
  • LFR2 having the amino acid sequence of SEQ ID NO: 12
  • LFR3 having the amino acid sequence of SEQ ID NO: 13
  • LFR4 having the amino acid sequence of SEQ ID NO: 14, or a variant thereof in which one or two or three amino acids in one or more of
  • LFR1, LFR2, LFR3, or LFR4 are substituted with another amino acid.
  • the antigen-binding domain that is capable of binding EGFR comprises a VL region comprising the CDRs according to (5) above, and the FRs according to (6) above.
  • the antigen-binding domain that is capable of binding EGFR comprises a VL region according to (7) below:
  • the antigen-binding domain that is capable of binding EGFR comprises a VH region according to any one of (1) to (4) above, and a VL region according to any one of (5) to (7) above.
  • the antigen-binding domain comprises a VH region according to any one of (1), (3) and (4) and a VL region according to one of (5) and (7).
  • the antigen-binding domain that is capable of binding cMET comprises the CDRs of an antibody which is capable of binding to cMET.
  • the antigenbinding domain that is capable of binding cMET additionally comprises the FRs of an antibody which is capable of binding to cMET. That is, in some embodiments the antigenbinding domain that is capable of binding cMET comprises the VH region and the VL region of an antibody which is capable of binding to cMET.
  • the antigen-binding domain that is capable of binding cMET comprises a VH region and a VL region which is, or which is derived from, the VH/VL region of a cMET-binding antibody clone described herein (i.e. anti-cMET antibody clone B09-GL).
  • the antigen-binding domain that is capable of binding cMET comprises the three HCDRs or three LCDRs, preferably the three VH CDRs and the three VL CDRs, of cMET-binding antibody clone B09-GL.
  • the VH and VL domain sequences of antibodies B09-GL are described herein, and the three VH and three VL domain CDRs of said antibodies may thus be determined from said sequences.
  • the antigen-binding domain that is capable of binding cMET comprises a VH region according to (8) below:
  • VH region comprising the following CDRs:
  • HCDR1 having the amino acid sequence of SEQ ID NO: 17
  • HCDR2 having the amino acid sequence of SEQ ID NO: 18
  • HCDR3 having the amino acid sequence of SEQ ID NO: 19.
  • the antigen-binding domain that is capable of binding cMET comprises a VH region according to (8) above, wherein the VH region additionally comprises the FRs according to (9) below:
  • HFR1 having the amino acid sequence of SEQ ID NO: 23
  • HFR2 having the amino acid sequence of SEQ ID NO: 24
  • HFR3 having the amino acid sequence of SEQ ID NO: 25
  • HFR4 having the amino acid sequence of SEQ ID NO: 26, or a variant thereof in which one or two or three amino acids in one or more of HFR1, HFR2, HFR3, or HFR4 are substituted with another amino acid.
  • the antigen-binding domain that is capable of binding cMET comprises a VH according to (10) below:
  • the antigen-binding domain that is capable of binding cMET comprises a VH region according to (11) below:
  • VH region comprising an amino acid sequence having at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO: 31.
  • the antigen-binding domain that is capable of binding cMET comprises a VL region according to (12) below:
  • VL region comprising the following CDRs:
  • LCDR1 having the amino acid sequence of SEQ ID NO: 20
  • LCDR2 having the amino acid sequence of SEQ ID NO: 21
  • LCDR3 having the amino acid sequence of SEQ ID NO: 22.
  • the antigen-binding domain that is capable of binding cMET comprises a VL region according to (12) above, wherein the VL region additionally comprises the FRs according to (13) below:
  • LFR4 having the amino acid sequence of SEQ ID NO: 30, or a variant thereof in which one or two or three amino acids in one or more of LFR1, LFR2, LFR3, or LFR4 are substituted with another amino acid.
  • the antigen-binding domain that is capable of binding cMET comprises a VL region according to (14) below: (14) a VL region comprising the CDRs according to (12) and the FRs according to
  • the antigen-binding domain that is capable of binding cMET comprises a VL region according to (15) below:
  • VL region comprising an amino acid sequence having at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO: 32.
  • the antigen-binding domain that is capable of binding cMET comprises a VH region according to any one of (8) to (11) above, and a VL region according to any one of (12) to (15) above.
  • the invention provides compounds (e.g., radioimmunoconjugates) comprising an antibody (i.e. a bispecific antibody) or antigen-binding fragment thereof conjugated to a radioactive payload, wherein the antibody or antigen-binding fragment thereof of the radioimmunoconjugate comprises a first antigen-binding domain that comprises the CDRs of an antigen-binding domain which is capable of binding to EGFR, and a second antigenbinding domain that comprises the CDRs of an antigen-binding domain which is capable of binding to cMET.
  • an antibody i.e. a bispecific antibody
  • antigen-binding fragment thereof of the radioimmunoconjugate comprises a first antigen-binding domain that comprises the CDRs of an antigen-binding domain which is capable of binding to EGFR, and a second antigenbinding domain that comprises the CDRs of an antigen-binding domain which is capable of binding to cMET.
  • the first antigen-binding domain comprises the CDRs and the FRs of an antigen-binding domain which is capable of binding to EGFR and the second antigen -binding domain comprises the CDRs and the FRs of an antigen-binding domain which is capable of binding to cMET.
  • the antibody or antigen-binding fragment of the compound e.g., radioimmunoconjugate
  • the first antigen-binding domain that is capable of binding EGFR comprises a VH region and a VL region which is, or which is derived from, the VH/VL region of the EGFR-binding antibody clone RAA22
  • the second antigen-binding domain that is capable of binding cMET comprises a VH region and a VL region which is, or which is derived from, the VH/VL region of the cMET -binding antibody clone B09-GL.
  • a bispecific antibody may be termed “RAA22/B09” or “RAA22/B09 bispecific antibody”.
  • the first antigen-binding domain comprises: a VH region according to any one of (1) to (4) above and a VL region according to any one of (5) to (7) above; and the second antigen -binding domain comprises: a VH region according to any one of (8) to (11) above, and a VL region according to any one of (12) to (15) above.
  • the compound (e.g., radioimmunoconjugate) of this invention comprises an antibody or antigen-binding fragment thereof comprising: a first antigen-binding domain that is capable of binding epidermal growth factor receptor (EGFR); and a second antigen-binding domain that is capable of binding cMET, wherein the first antigen-binding domain comprises:
  • VH heavy chain variable region comprising the following complementarity determining regions (CDRs):
  • HCDR1 having the amino acid sequence of SEQ ID NO: 1
  • HCDR2 having the amino acid sequence of SEQ ID NO: 2
  • HCDR3 having the amino acid sequence of SEQ ID NO: 3;
  • VL light chain variable
  • LCDR1 having the amino acid sequence of SEQ ID NO: 4
  • LCDR2 having the amino acid sequence of SEQ ID NO: 5
  • LCDR3 having the amino acid sequence of SEQ ID NO: 6.
  • the first antigen-binding domain comprises: a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 15; and a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 16, and/or the second antigen-binding domain comprises: a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 31; and a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 32.
  • the antibody or antigen-binding fragment thereof of the compound (e.g., radioimmunoconjugate) described herein comprises an immunoglobulin heavy chain constant (CH) region.
  • the CH is, or is derived from, the heavy chain constant sequence of an IgG (e.g., IgGl, IgG2, IgG3, IgG4), IgA (e.g., IgAl, IgA2), IgD, IgE or IgM.
  • the CH region is human immunoglobulin G1 constant (IGHG1; UniProt: P01857-1, vl; SEQ ID NO: 33) or a fragment thereof.
  • the CH region comprises an amino acid sequence having at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of SEQ ID NO: 39 or 40.
  • the antibody or antigen-binding fragment thereof of the compound comprises a heavy chain that comprises or consists of a VH region as described herein and a CH region as described herein.
  • the antibody or antigen-binding fragment thereof of the compound (e.g., radioimmunoconjugate) described herein comprises an immunoglobulin light chain constant (CL) region or a fragment thereof.
  • CL immunoglobulin light chain constant
  • the CL region is, or is derived from a kappa CL region set forth in SEQ ID NO: 34.
  • the CL region is, or is derived from a lambda CL region set forth in SEQ ID NO: 41.
  • the antibody or antigen-binding fragment thereof of the compound comprises: a first CL region that is, or is derived from, a kappa CL region set forth in SEQ ID NO: 34; and a second CL region that is, or is derived from, a lambda CL region set forth in SEQ ID NO: 41.
  • the antibody or antigen-binding fragment thereof of the compound (e.g., radioimmunoconjugate) described herein comprises: a first heavy chain, wherein the first heavy chain comprises the VH region of the first antigen-binding domain, and a first heavy chain constant (CH) region or a fragment thereof; a first light chain, wherein the first light chain comprises the VL region of the first antigen-binding domain, and a first light chain constant (CL) region or a fragment thereof; a second heavy chain, wherein the second heavy chain comprises the VH region of the second antigen-binding domain, and a second heavy chain constant (CH) region or a fragment thereof; and a second light chain, wherein the second light chain comprises the VL region of the second antigen-binding domain, and a second light chain constant (CL) region or a fragment thereof.
  • a first heavy chain wherein the first heavy chain comprises the VH region of the first antigen-binding domain, and a first heavy chain constant (CH) region or a fragment thereof
  • an antibody or antigen-binding fragment thereof comprises a first VH region and a first CH region, that these regions together form a first heavy chain of the antibody or antigen-binding fragment thereof, that is that the first VH and first CH regions are connected to each other.
  • a second VH region and a second CH region forms a second heavy chain of the antibody or antigen-binding fragment thereof;
  • a first VL region and a first CL region form a first light chain of the antibody or antigenbinding fragment thereof;
  • a second VL region and a second CL region form a second light chain of the antibody or antigen-binding fragment thereof.
  • the antibody or antigen-binding fragment thereof of the compound comprises a first and second heavy chain, wherein
  • the first heavy chain comprises an amino acid sequence which has at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of the heavy chain set forth in SEQ ID NO: 35; and
  • the second heavy chain comprises an amino acid sequence which has at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of the heavy chain set forth in SEQ ID NO: 36.
  • the antibody or antigen-binding fragment thereof of the compound (e.g., radioimmunoconjugate) described herein comprises a light chain that comprises or consists of a VL region as described herein and a CL region as described herein.
  • the antibody or antigen-binding fragment thereof of the compound (e.g., radioimmunoconjugate) described herein comprises a first and second light chain, wherein
  • the first light chain comprises an amino acid sequence which has at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of the light chain set forth in SEQ ID NO: 37; and
  • the second light chain comprises an amino acid sequence which has at least 70% sequence identity, more preferably one of at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, sequence identity to the amino acid sequence of the light chain set forth in SEQ ID NO: 38.
  • the CH, CL, heavy chain and/or light chain of the antibody or antigen-binding fragment thereof of the compounds (e.g., radioimmunoconjugates) described herein may comprise one or more modifications, for example to abrogate or reduce Fc effector functions, promote formation of a heterodimeric antibody or antigen-binding fragment thereof, to increase the efficacy of cognate heavy and light chain pairing, and/or to assist with conjugate formation as described in more detail below.
  • a CH, CL, heavy chain and light chain that has been modified may be referred to as a modified CH, CL, heavy chain and light chain, respectively.
  • the antibody or antigen-binding fragment thereof of the compound may comprise a mutation in the CH region(s) of the heavy chain(s) to reduce or abrogate binding of the antibody or antigen-binding fragment thereof to one or more Fey receptors, such as FcyRI, FcyRIIa, FcyRIIb, FcyRIII and/or to complement.
  • Fey receptors such as FcyRI, FcyRIIa, FcyRIIb, FcyRIII and/or to complement.
  • Such mutations abrogate or reduce Fc effector functions.
  • Mutations for reduce or abrogate binding of an antibody to one or more Fey receptors and complement are known and include the “triple mutation” or “TM” of L234F/L235E/P331S described for example in Organesyan, 2008.
  • Other mutations that are known to modulate antibody effector function are described for example in Wang, 2018.
  • CH regions comprising the triple mutation are SEQ ID NOs: 39 and 40.
  • one of the first and second heavy chains comprises a CH region having an amino acid sequence having at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 39 and the other heavy chain comprises a CH region having an amino acid sequence having at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 40, wherein one or both (preferably both) of the CH regions comprise a phenylalanine at position 234, glutamic acid at position 235, and serine at position 331, wherein the numbering is as per the EU index.
  • Examples of heavy chains of the disclosure comprising a CH region containing the triple mutation are SEQ ID NOs: 35 and 36.
  • one of the first and second heavy chains has an amino acid sequence having at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 35 and the other heavy chain has an amino acid sequence having at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to the sequence set forth in SEQ ID NO: 36, wherein one or both (preferably both) of the have chains comprise a phenylalanine at position 234, glutamic acid at position 235, and serine at position 331, wherein the numbering is as per the EU index.
  • VL and CL region, and the VH region and CHI region of an antibody or antigen-binding fragment thereof of the compound together constitute the Fab region.
  • the remainder of the antibody or antigen-binding fragment thereof of the compound constitute the Fc region.
  • amino acid residue positions in the constant domain including the position of amino acid sequences, substitutions, deletions and insertions as described herein, are numbered according to EU numbering (Edelman, 2007).
  • the disclosure provides asymmetrical IgG-like bispecific antibodies or antigenbinding fragments thereof within the compound (e.g., radioimmunoconjugates) disclosed herein.
  • Asymmetrical bispecific molecules are typically monovalent for each target.
  • the concept of monovalent bispecific IgG is thought to have a unique therapeutic niche in that they (i) do not cause receptor homodimerization, (ii) potentially have reduced toxicity on non-target tissues due to loss of avidity for each antigen, and (iii) have better selectivity when both antigens are either selectively restricted or abundantly expressed on target cells.
  • the antibody or antigenbinding fragment thereof is an asymmetrical IgG-like bispecific antibody or antigen-binding fragment thereof.
  • Asymmetrical IgG-like bispecific antibodies involve heterodimerization of two distinct heavy chain and correct pairing of the cognate light chain and heavy chain. Heterodimerization of the heavy chains can be addressed by several techniques, such as knobs-into-holes, electrostatic steering of CH3, CH3 strand exchanged engineered domains and leucine zippers.
  • the pairing of the correct light and heavy chain can be ensured by using one of these heavy chain heterodimerization techniques along with the use of a common light chain, domain cross-over between CHI and CL, coupling of the heavy and light chains with a linker, in vitro assembly of heavy chain-light chain dimers from two separate monocl onals, interface engineering of an entire Fab domain, or disulfide engineering of the CH1/CL interface.
  • DuetMab A particular exemplified format of asymmetrical IgG-like bispecific antibodies is referred to as “DuetMab”. DuetMab antibodies uses KIH technology for heterodimerization of 2 distinct heavy chains and increases the efficacy of cognate heavy and light chain pairing by replacing the native disulphide bond in one of the CHI -CL interfaces with an engineered disulphide bond. Disclosure related to DuetMab can found e.g., in U.S. Pat. No. 9,527,927 and Mazor, 2015, which are herein incorporated by reference in their entirety.
  • the antibody or antigen-binding fragment thereof of the compound comprises:
  • modified CL comprises a substitution of a native non-cysteine amino acid to a cysteine amino acid, wherein either:
  • the first heavy chain comprises the modified CH region and the first light chain comprises the modified corresponding CL region;
  • the second heavy chain comprises the modified CH region and the second light chain comprises the modified corresponding CL region.
  • the substituted cysteine of the modified CH region, resulting from the substitution of the native non-cysteine amino acid to the cysteine amino acid, and the substituted cysteine of the modified corresponding CL region, resulting from the substitution of the native non-cysteine amino acid to the cysteine amino acid can form a disulphide bond.
  • the modified CH region comprises a substitution of a native non-cysteine amino acid to a cysteine amino acid at position 126; and the modified corresponding CL region comprises a substitution of a native non-cysteine amino acid to a cysteine at position 121, wherein the numbering of the constant region is as per the EU index.
  • the modified CH region comprises a substitution of a native non-cysteine amino acid to a cysteine amino acid at position 126 and a substitution of a native cysteine amino acid to a non-cysteine amino acid at position 219, for example to a valine; and the modified corresponding CL region comprises a substitution of a native non- cysteine amino acid to a cysteine at position 121 and a substitution of a native cysteine amino acid to a non-cysteine amino acid at position 214, for example to a valine, where the numbering of the constant region is as per the EU index.
  • the antibody or antigen-binding fragment thereof comprises a second CH region and a second corresponding light chain, wherein the second CH region and second corresponding CL do not comprise a substitution of a native non-cysteine amino acid to a cysteine amino acid and do not comprise a substitution of a native cysteine to a non- cysteine amino acid.
  • the antibodies or antigen-binding fragments thereof of the radioimmunoconjugates described herein may be characterized by the antigen-binding domain that is capable of binding EGFR having a particular affinity for EGFR and/or the antigen-binding domain that is capable of binding cMET having a particular affinity for cMET.
  • the binding affinity of an antibody or antigen-binding fragment thereof of the compound (e.g., radioimmunoconjugate) to a cognate antigen, such as human, mouse or cynomolgus EGFR or cMET can be determined by surface plasmon resonance (SPR), using Biacore, for example.
  • the binding affinity can be determined using an antibody or antigen-binding fragment thereof, for example as part of a bispecific antibody that comprises a first antigen-binding domain that is capable of binding EGFR and a second antigen-binding domain that is capable of binding cMET.
  • the binding affinity can be determined using an antibody or antigenbinding fragment thereof that is monospecific for EGFR or cMET.
  • the binding affinity is determined using BIACore as provided herein or known in the field.
  • Binding affinity is typically measured by Kd (the equilibrium dissociation constant between the antigen-binding domain and its antigen). As is well understood, the lower the Kd value, the higher the binding affinity of the antigen-binding domain. For example, an antigen-binding domain that is capable of binding to a target with a Kd of 10 nM would be considered to be binding said target with a higher affinity than an antigen-binding domain that is capable of binding to the same target with a Kd of 100 nM.
  • Reference to human EGFR may refer to a polypeptide comprising the extracellular domain of EGFR, such as one having the amino acid sequence set forth in SEQ ID NO: 42.
  • Reference to mouse EGFR may refer to a polypeptide produced from the molecule available from SinoBiological with catalogue # 51091-M08H.
  • Reference to cynomolgus EGFR may refer to the amino acid sequence set forth in SEQ ID NO: 46.
  • Reference to human cMET may refer to a polypeptide having the amino acid sequence set forth in SEQ ID NO: 43.
  • Reference to mouse cMET may refer to a polypeptide produced from the molecule available from SinoBiological with catalogue # 50622-M08H.
  • Reference to cynomolgus cMET may refer to the amino acid sequence set forth in SEQ ID NO: 44.
  • the antibodies or antigen-binding fragments thereof of the compounds (e.g., radioimmunoconjugates) described herein may comprise an antigen-binding domain that is capable of binding EGFR with a low affinity.
  • low affinity refers to a first antigen-binding domain that is capable of binding human EGFR with a dissociation constant (Kd) that is equal to or higher than 10 nM.
  • Antibodies or antigen-binding fragments of the compounds (e.g., radioimmunoconjugates) described herein comprising such a low affinity EGFR antigen-binding domain may display reduced on-target toxicity in normal tissues such as skin toxicity and therefore have an improved safety profile compared to conjugates comprising an EGFR antigen-binding domain that is capable of binding human EGFR with a “higher affinity”.
  • “higher affinity” or “high affinity” refers to a first antigen binding domain that is capable of binding human EGFR with a Kd that is lower than 10 nM.
  • the antigen-binding domain that is capable of binding EGFR may bind to human EGFR with an affinity having a Kd equal to or higher than 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 35 nM, or 40 nM.
  • the antigen-binding domain that is capable of binding EGFR may bind to human EGFR with a Kd of between 10 and 100 nM, between 20 and 100 nM, between 30 and 100 nM, between 40 and 100 nM, between 10 and 80 nM, between 20 and 80 nM, between 30 and 80 nM, between 40 and 80 nM, between, between 10 and 70 nM, between 20 and 70 nM, between 30 and 70 nM, between 40 and 70 nM, between 10 and 60 nM, between 20 and 60 nM, between 30 and 60 nM, between 40 and 60 nM, between 10 and 50 nM, between 20 and 50 nM, between 30 and 50 nM, or between 40 and 50 nM.
  • the antigen-binding domain that is capable of binding EGFR may bind to human EGFR with an affinity that is lower than the affinity of an antigen-binding domain comprising the variable heavy (VH) region sequence and variable light (VL) region sequence of antibody QD6, as set forth in SEQ ID NOs: 47 and 48, respectively.
  • VH variable heavy
  • VL variable light
  • the antigen-binding domain that is capable of binding EGFR may bind to human EGFR with an affinity having a Kd that is at least 2-fold, 3-fold, 4-fold, 5- fold, 6-fold, or 7-fold higher than the Kd at which an antigen-binding domain comprising the heavy chain sequence and light chain sequence of antibody QD6 set forth in SEQ ID NOs: 47 and 48, respectively, binds human EGFR.
  • the antigen-binding domain that is capable of binding EGFR may bind to human EGFR with an affinity having a Kd that is between 2- and 10-fold higher, between 3- and 10-fold higher, between 4- and 10-fold higher, between 5- and 10-fold higher, between 6- and 10-fold higher, between 7- and 10-fold higher, between 2- and 9-fold higher, between 3- and 9-fold higher, between 4- and 9-fold higher, between 5- and 9-fold higher, between 6- and 9-fold higher, between 7- and 9-fold higher, between 2- and 8-fold higher, between 3- and 8-fold higher, between 4- and 8-fold higher, between 5- and 8-fold higher, between 6- and 8-fold higher, between 7- and 8-fold higher than the Kd at which an antigen-binding domain comprising the heavy chain sequence and light chain sequence of antibody QD6 set forth in SEQ ID NOs: 47 and 48, respectively, binds human EGFR.
  • the antigen-binding domain that is capable of binding EGFR may bind to human EGFR with an affinity that is similar to the affinity that an antigen-binding domain comprising the variable heavy region sequence and variable light region sequence of antibody RAA22 set forth in SEQ ID NOs: 15 and 16, respectively.
  • the antigen-binding domain that is capable of binding EGFR may bind to human EGFR with an affinity having a Kd that is less than 5-fold different, less than 4-fold different, less than 3-fold different, less than 2-fold different, less than 1-fold different or less than 0.5-fold different than the Kd at which an antigen-binding domain comprising the variable heavy region sequence and variable light region sequence of antibody RAA22 set forth in SEQ ID NOs: 15 and 16, respectively, binds human EGFR.
  • the antigen-binding domain that is capable of binding EGFR may also be capable of binding cynomolgus EGFR.
  • the antigen-binding domain that is capable of binding EGFR may bind to cynomolgus EGFR with an affinity having a Kd that is less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, or less than 250 nM.
  • the antigen-binding domain that is capable of binding EGFR may bind to cynomolgus EGFR with an affinity having a Kd of between 100 and 700 nM, between 100 and 600 nM, between 100 and 500 nM, between 100 and 400 nM, between 100 and 300 nM, between 150 and 250 nM, between 100 and 200 nM.
  • the antigen-binding domain that is capable of binding EGFR may bind to cynomolgus EGFR with a Kd that is less than or equal 10-, 9-, 8-, 7-, 6-, 5-, 4-, 3-fold higher Kd than the antigen-binding domain binds to human EGFR.
  • the antigen-binding domain is capable of binding EGFR may also be capable of binding mouse EGFR.
  • the antigen-binding domain that is capable of binding EGFR may bind to mouse EGFR with an affinity having a Kd that is less than 1 pM, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM or less than 650 nM.
  • the antigen-binding domain that is capable of binding EGFR may bind to mouse EGFR with a Kd of between 100 nM and 1 pM, between 200 and 900 nM, between 300 and 800 nM, between 400 and 700 nM, between 400 and 600 nM, or between 450 and 550 nM.
  • the antigen-binding domain that is capable of binding EGFR is capable of binding human EGFR and cynomolgus EGFR.
  • This cross-reactivity is advantageous, as it allows dosing and safety testing of the antibodies and conjugates to be performed in cynomolgus monkeys during preclinical development.
  • the antigenbinding domain that is capable of binding EGFR is capable of binding human EGFR, cynomolgus EGFR and mouse EGFR.
  • the antigen-binding domain that is capable of binding EGFR may be capable of binding human EGFR, cynomolgus EGFR and mouse EGFR with the Kd values set out above (e.g.
  • the antigen-binding domain that is capable of binding cMET may bind to human cMET with an affinity having a Kd of lower than 20 nM, 15 nM, 12 nM, 11 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM or 2.5 nM.
  • antigen-binding domain that is capable of binding cMET may bind to human cMET with an affinity having a Kd of between 1 and 20 nM, between 1 and 15 nM, between 1 and 10 nM, between 1 and 9 nM, between 1 and 8 nM, between 1 and 7 nM, between 1 and 6 nM, between 1 and 5 nM, between 1 and 4 nM, between 1 and 3 nM, between 1 and 2.5 nM, or between 2 and 2.5 nM.
  • the antigen-binding domain that is capable of binding cMET may be capable of binding cynomolgus cMET.
  • the antigen-binding domain that may be capable of binding cMET may bind to cynomolgus cMET with an affinity having a Kd that is lower than 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, or 2.5 nM.
  • the antigen-binding domain that is capable of binding cMET may bind to cynomolgus cMET with an affinity having a Kd of between 1 and 20 nM, between 1 and 15 nM, between 1 and 10 nM, between 1 and 9 nM, between 1 and 8 nM, between 1 and 7 nM, between 1 and 6 nM, between 1 and 5 nM, between 1 and 4 nM, between 1 and 3 nM, between 1 and 2.5 nM, or between 2 and 2.5 nM.
  • the antigen-binding domain that is capable of binding cMET may bind to cynomolgus cMET with an affinity having a Kd that is less than or equal 10-, 9-, 8-, 7-, 6-, 5-, 4-, 3-, 2-, 1-fold higher Kd than the antigen-binding domain binds to human cMET.
  • the antigen-binding domain that is capable of binding cMET is capable of binding human cMET and cynomolgus cMET.
  • This cross-reactivity is advantageous, as it allows dosing and safety testing of the antibodies to be performed in cynomolgus monkeys during preclinical development.
  • the antigen-binding domain that is capable of binding cMET may be capable of binding human cMET and cynomolgus cMET with the Kd values set out above (e.g., human cMET with a Kd of between 1 and 20 nM and cynomolgus cMET with a Kd of between 1 and 20 nM).
  • the antibodies or antigen-binding fragments thereof of the compounds (e.g., radioimmunoconjugates) described herein may comprise an antigen-binding domain that is capable of specifically binding EGFR.
  • the antibodies or antigen-binding fragments of the compounds (e.g., radioimmunoconjugates) described herein may comprise an antigenbinding domain that is capable of specifically binding cMET.
  • the antibodies or antigenbinding fragments of the compounds (e.g., radioimmunoconjugates) described herein may comprise a first antigen-binding domain that is capable of binding EGFR, which is a first antigen-binding domain that is capable of specifically binding EGFR, and a second antigenbinding domain that is capable of binding cMET, which is a first antigen-binding domain that is capable of specifically binding cMET.
  • the term “specific” may refer to the situation in which the antigen-binding domain will not show any significant binding to molecules other than its specific binding partner(s), here, EGFR or cMET. Such molecules are referred to as “non-target molecules”.
  • the term “specific” is also applicable where the antibody or antigen-binding fragment thereof is specific for particular epitopes, such as epitopes on EGFR or cMET, that are carried by a number of antigens in which case the antibody or antigen-binding fragment thereof will be able to bind to the various antigens carrying the epitope.
  • an antibody or antigen-binding fragment thereof of the compound is considered to not show any significant binding to a non-target molecule if the extent of binding to a non-target molecule is less than about 10% of the binding of the antibody or antigen-binding fragment thereof to the target as measured, e.g., by ELISA, SPR, Bio-Layer Interferometry (BLI), MicroScale Thermophoresis (MST), or by a radioimmunoassay (RIA).
  • the binding specificity may be reflected in terms of binding affinity, where the antibodies or antigen-binding fragments thereof of the compounds (e.g., radioimmunoconjugates) described herein are capable of binding to EGFR and/or cMET with an affinity that is at least 0.1 order of magnitude greater than the affinity towards another, non-target molecule.
  • the antibodies or antigen-binding fragments thereof of the compounds (e.g., radioimmunoconjugates) described herein are capable of binding to EGFR and/or cMET with an affinity that is at least 0.1 order of magnitude greater than the affinity towards another, non-target molecule.
  • the antibody or antigen-binding fragment thereof of the compound (e.g., radioimmunoconjugate) of the present disclosure is capable of binding to EGFR and/or cMET with an affinity that is one of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, or 2.0 orders of magnitude greater than the affinity towards another, non-target molecule.
  • EGFR is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR, HER2, HER3 and HER4.
  • the RAA22 antigenbinding domain showed no binding to HER2, HER3 and HER4, demonstrating that this antigen-binding domain binds EGFR specifically.
  • the antigenbinding domain that is capable of binding EGFR does not bind, or does not show any significant binding, to HER2, HER3 or HER4.
  • cMET is a member of the subfamily of receptor tyrosine kinases that includes Ron and Serna 4a.
  • the B09-GL antigen-binding domain showed no binding to Ron and Serna 4a, demonstrating that this antigen-binding domain binds cMET specifically.
  • the antigen-binding domain that is capable of binding cMET does not bind, or does not show any significant binding, to Ron, Serna 4a.
  • the antibodies or antigen-binding fragments thereof of the compounds (e.g., radioimmunoconjugates) in the present disclosure comprising a first antigen-binding domain that is capable of binding EGFR and a second antigen-binding domain that is capable of binding cMET described herein may be characterized by the ability of both the antigenbinding domains to concurrently engage their respective EGFR and cMET targets.
  • Antibodies or antigen-binding fragments thereof of the presently disclosed compounds e.g., radioimmunoconjugates
  • the antibody or antigen-binding fragment thereof of the presently disclosed compounds is able to concurrently engage EGFR and cMET.
  • the antibodies or antigen-binding fragments thereof of the compounds (e.g., radioimmunoconjugates) described herein may be characterised by their ability to mediate efficient internalisation.
  • an antibody or antigen-binding fragment thereof or compound (e.g., radioimmunoconjugate) comprising said antibody or antigen-binding fragment thereof) by cells can be analysed by contacting live cells with the antibody or antigen-binding fragment thereof, and detecting the antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) after sufficient period of time for internalisation. Internalisation can be determined by detection of the localisation of the antibody (or antigenbinding fragment thereof) or compound (e.g., radioimmunoconjugate).
  • the antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) remains on the surface of the cell (e.g., is detected on the cell surface, and/or is not detected inside the cell), the antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) is determined not to have been internalised.
  • the antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) is detected inside the cell (e.g., localised to the cytoplasm or a cellular organelle), the antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) is determined to have been internalised.
  • An exemplary method for visualising whether the antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) is able to mediate efficient internalisation involves labelling the antibody with pH sensitive dyes that exhibit fluorescent at an acidic pH and adding these labelled antibodies or conjugates to cells. Internalisation into the cell can be detected by monitoring fluorescence.
  • the antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) is considered able to mediate internalisation and delivery to lysosomes if the fluorescence observed is greater than that of a labelled non-binding control antibody (or antigen-binding fragment thereof) or compound (e.g., radioimmunoconjugate) over a certain time period, for example 48 hours. Further details of this method to visualise antibody (or antigen-binding fragment thereof) internalisation can be found in the examples.
  • the antibodies or antigen-binding fragments thereof of the compounds comprising a first antigen-binding domain that is capable of binding EGFR and a second antigen-binding domain that is capable of binding cMET may be characterised by their ability to mediate more efficient internalisation when compared to the EGFR or cMET monospecific controls.
  • Antibodies or antigen-binding fragments thereof of compounds (e.g., radioimmunoconjugates) that exhibit this property are expected to be advantageous, as they are expected to display greater selectivity to tumor cells co-expressing both targets and could minimise the impact of the antibody or antigen-binding fragment thereof in normal tissues that do not display significant levels of co-expression.
  • compounds comprising antibodies or antigen-binding fragments that comprise a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises a CDR-H1, CDR-H2, and CDR-H3, and the light chain variable domain comprises a CDR-L1, CDR-L2, and CDR-L3, wherein the CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3, are those of an antibody described in the Sequence Annex provided below.
  • compounds comprising antibodies or antigen-binding fragments that are variants of the antibodies shown in Sequence Annex, in that such antibodies or antigenbinding fragments have CDR sequences that differ by no more than three amino acid residues (e.g., three or two or one amino acid residue(s)) per CDR from the CDR sequences of an antibody described in Sequence Annex.
  • compounds comprising antibodies or antigenbinding fragments that are variants of the antibodies shown in Sequence Annex, in that such antibodies or antigen-binding fragments have a set of six CDRs whose sequences collectively differ by no more than three amino acid residues (e.g., three or two or one amino acid residues) from the CDRs of an antibody described in Sequence Annex.
  • kits comprising antibodies or antigen-binding fragments that comprise a heavy chain variable domain and a light chain variable domain which comprise heavy chain variable domain and light chain variable sequences of an antibody described in Sequence Annex.
  • compounds comprising antibodies or antigen-binding fragments that are variants of the antibodies shown in Sequence Annex, in that such antibodies or antigenbinding fragments have (1) a heavy chain domain comprising an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the heavy chain variable domain of an antibody described in Sequence Annex; and (2) a light chain domain comprising an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of a light chain variable domain of the
  • HCDR2 - AIVAVFRTETYAQKFQD (SEQ ID NO: 2)
  • HCDR3 - RLMSAISGPGAPLLM (SEQ ID NO: 3)
  • LCDR1 - TGTSSDVGGYNYVS (SEQ ID NO: 4)
  • LCDR2 - DVSKRPS (SEQ ID NO: 5)
  • HFR3 - RVKITADISTRTTYMELSSLRSEDTAVYYCAR (SEQ ID NO: 9)
  • HFR4 - WGQGTLVTVSS (SEQ ID NO: 10)
  • LFR3 - GVPDRFSGSKSGNTASLTISGLQAEDEADYYC (SEQ ID NO: 13)
  • LFR4 - FGGGTKLTVL (SEQ ID NO: 14)
  • Amino acid sequence of the variable heavy (VH) region of anti-EGFR antibody clone RAA22 (SEQIDNO: 15)
  • VQLVQSGAEVKKPGS S VKVSCKASGGTF SDNDF SWVRQ APGQGLEWMGAIVAVF RTETYAQKFQDRVKITADISTRTTYMELSSLRSEDTAVYYCARRLMSAISGPGAPLL MWGQGTLVTVSS
  • VL variable light region of anti-EGFR antibody clone RAA22
  • VH variable heavy region of anti-c-Met antibody clone B09-GL
  • TMVTVSS Amino acid sequence of the variable light (VL) region of anti-c-Met antibody clone B09-GL (SEQIDNO: 32):
  • Amino acid sequence of a wild-type human immunoglobulin kappa constant region (SEQ ID NO: 34):
  • Amino acid sequence of the heavy chain of anti-EGFR in ‘EGFR-cMET TM” antibody (SEQ ID NO: 35):
  • T366W Triple mutation (TM; L234F, L235E and P331S); “Knob” mutation (T366W); interchain cysteine mutations (F126C and C219V); stabilizing cysteine mutation (S354C), where numbering of residues is according to EU index.
  • VQLVQSGAEVKKPGS S VKVSCKASGGTF SDNDF SWVRQ APGQGLEWMGAIVAVF RTETYAQKFQDRVKITADISTRTTYMELSSLRSEDTAVYYCARRLMSAISGPGAPLL MWGQGTLVTVSSASTKGPSVCPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS VDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAI ⁇ TI ⁇ PREEQYNSTYRVVSVLTVLHQDWLNGI ⁇ EYI ⁇ CI ⁇ VSNI ⁇ ALPA SIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTV
  • Amino acid sequence of the light chain of anti-EGFR in “EGFR-cMET TM” antibody (SEQ ID NO: 37):
  • Amino acid sequence of the light chain of anti-c-Met in “EGFR-cMET TM” antibody (SEQ ID NO: 38):
  • Amino acid sequence of a human immunoglobulin G1 CH region modified to include “knob ” mutations, a cysteine to form a stabilizing disulfide bridge, without a cysteine insertion and with the TM (SEQ ID NO: 39):
  • Triple mutation (TM; L234F, L235E and P331S); “Knob” mutation (T366W); interchain cysteine mutations (F126C and C219V); stabilizing cysteine mutation (S354C), where numbering of residues is according to EU index.
  • Triple mutation (TM; L234F, L235E and P331S); “Hole” mutations (T366S, L368A, and Y407V); and stabilizing cysteine mutation (Y349C), where numbering of residues is according to EU index.
  • Amino acid sequence of a human immunoglobulin lambda constant region modified to include S121C and C214V substitutions (SEQ ID NO: 41):
  • Amino acid sequence of the VH region of anti-EGFR antibody clone QD6 (SEQ ID NO: 47):
  • VQLVQSGAEVKKPGS S VKVSCKASGGTF SDNDF SWVRQ APGQGLEWMGAIVAVV RTETYAQKFQDRVKITADISTRTTYMELSSLRSEDTAVYYCARRLMSAISGPGAPLL MWGQGTLVTVSS
  • Amino acid sequence of the VL region of anti-EGFR antibody clone QD6 (SEQ ID NO: 48):
  • chelating moieties include, but are not limited to, DOTA (l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid), DOTMA (lR,4R,7R,10R)-a, a’, a”, a”’-tetramethyl-l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid, DOTAM (1 ,4,7, 10-tetrakis(carbamoylmethyl)- 1 ,4,7, 10-tetraazacyclododecane), DOTP A ( 1 ,4,7, 10- tetraazacyclododecane-l,4,7,10-tetra propionic acid), DO3AM-acetic acid (2-(4,7,10-tris(2- amino-2-oxoethyl)-l,4,7,10-tetraazacyclodo
  • the chelating moiety is selected from DOTA (1,4,7,10- tetraazacyclododecane-l,4,7,10-tetraacetic acid), DOTMA (lR,4R,7R,10R)-a, a’, a”, a’”- tetramethyl-l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid, DOTAM (1,4,7,10- tetrakis(carbamoylmethyl)-l,4,7,10-tetraazacyclododecane), DO3AM-acetic acid (2-(4,7,10- tris(2-amino-2-oxoethyl)-l,4,7,10-tetraazacyclododecan-l-yl)acetic acid), DOTP (1,4,7,10- tetraazacy clododecane- 1,4, 7,
  • the chelating moiety is DOTA.
  • compounds comprise a metal complex of a chelating moiety.
  • chelating groups may be used in metal chelate combinations with metals, such as manganese, iron, and gadolinium and isotopes (e.g., isotopes in the general energy range of 60 to 10,000 keV), such as any of the radioisotopes and radionuclides discussed herein.
  • chelating moieties are useful as detection agents, and compounds comprising such detectable chelating moieties can therefore be used as diagnostic or theranostic agents.
  • the metal complex comprises a radionuclide.
  • suitable radioisotopes and radionuclides include, but are not limited to, 3 H, 14 C, 15 N, 18 F, 35 S, 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 67 Ga, 67 Cu, 68 Ga, 75 Br, 76 Br , 77 Br , 82 Rb, 89 Zr, 86 Y, 87 Y, 90 Y, 97 RU, "TC, " m Tc, 105 Rh, 109 Pd, m In, 123 I, 124 I, 125 I, 131 I, 149 Pm, 149 Tb, 153 Sm, 166 HO, 177 LU, 117m Sn, 186 Re, 188 Re, 198 Au, 199 Au, 2O1 T1, 203 Pb, 211 At, 212 Pb , 212 Bi, 213 Bi, 223
  • the metal complex comprises a radionuclide selected from 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y, 87 Y, 89 Zr, 90 Y, 97 Ru, 99 Tc, " m Tc, 105 Rh, 109 Pd, m In, 117m Sn, 149 Pm, 149 Tb, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 198 Au, 199 Au, 2O1 T1, 203 Pb, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227Th , and 229Th .
  • a radionuclide selected from 44 Sc, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y,
  • the metal complex comprises a radionuclide selected from 68 Ga, 89 Zr, 90 Y, ni In, 177 Lu, and 225 Ac. In certain embodiments, the metal complex comprises a radionuclide of 177 Lu or 225 Ac.
  • the radionuclide is an alpha emitter, e.g., Astatine-21 1 ( 211 At), Bismuth-212 ( 212 Bi), Bismuth-213 ( 213 Bi), Actinium-225 ( 225 Ac), Radium-223 ( 223 Ra), Lead-212 ( 212 Pb), Thorium-227 ( 227Th ), or Terbium- 149 ( 149 Tb), or a progeny thereof.
  • the alpha-emitter is Actinium-225 ( 225 Ac), or a progeny thereof.
  • the metal complex comprises an alpha emitter of 225 Ac or a progeny thereof.
  • the compounds of this invention comprise the structure of Formula I below: A-L ⁇ L ⁇ n-B Formula I wherein each of the variables is defined in the SUMMARY section above.
  • Each of the compounds of Formula I comprises a linker moiety as -L 1 - ⁇ 2 )]!-, wherein:
  • X 1 is-C(O)NR'-*, -NR ⁇ O)-*, -C(S)NR 1 -*, -NR 3 C(S)-*, -OC(O)NR'-*, - NR 1 C(O)O-*, -NR 1 C(O)NR 1 -*, -CH 2 -Ph-C(O)NR 1 -*, -NR ⁇ C ⁇ -Ph-CIU-*, -CH 2 -Ph- NH-C(S)NR 1 -*, -NR ⁇ -NH-Ph-CJfc-*, -O-*, or -NR 1 -*; wherein indicates the attachment point to L 3 , and R 1 is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, or optionally substituted aryl or heteroaryl;
  • L 3 is optionally substituted C1-C50 alkyl or optionally substituted C1-C50 heteroalkyl (e.g., (CH 2 CH 2 0) 2-2 O); and
  • Z 1 is -CH 2 -#, -C(O)- #, -C(S)- #, -OC(O)-#, -C(O)O-#, -NR 2 C(O)-#, -C(O)NR 2 -#, or -NR 2 -#, wherein “#” indicates the attachment point to B, and R 2 is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • L 1 is optionally substituted Ci-Ce alkyl or optionally substituted Ci-Ce heteroalkyl.
  • L 1 is substituted Ci-Ce alkyl or substituted Ci-Ce heteroalkyl, the substituent comprising a heteroaryl group (e.g., sixmembered nitrogen-containing heteroaryl).
  • L 1 is Ci-Ce alky.
  • L 1 is -CH 2 CH 2 -
  • L 1 is a bond.
  • L 1 is , wherein R is hydrogen or -CO 2 H.
  • X 1 is-C(O)NR 1 -*, -NR 1 ⁇ )-*, or -NR 1 -, indicating the attachment point to L 3
  • R 1 is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • X 1 is -C(O)NR 1 -*, indicating the attachment point to L 3
  • R 1 is hydrogen.
  • L 3 is optionally substituted C1-C50 alkyl (e.g., C3-C30 alkyl, C3-C25 alkyl, C3-C20 alkyl, C 3 -Ci 5 alkyl, C3-C10 alkyl, C 5 -C 3 o alkyl, C 5 -C 25 alkyl, C 5 -C 2 o alkyl, C5-C15 alkyl, and C5-C10 alkyl) or optionally substituted C1-C50 heteroalkyl (e.g., C3- C30 heteroalkyl, C3-C25 heteroalkyl, C3-C20 heteroalkyl, C3-C15 heteroalkyl, C3-C10 heteroalkyl, C5-C30 heteroalkyl, C5-C25 heteroalkyl, C5-C20 heteroalkyl, C5-C15 heteroalkyl, and C5-C10 heteroalkyl).
  • C1-C50 alkyl e
  • An exemplary C1-C50 heteroalkyl is C5-C30 polyethylene glycol (e.g., C5-C25 polyethylene glycol, C5-C20 polyethylene glycol, C5-C15 polyethylene glycol).
  • L 3 is C5-C25 polyethylene glycol, C5-C20 polyethylene glycol, or C5-C15 polyethylene glycol.
  • L 3 is optionally substituted C1-C50 heteroalkyl (e.g., C1-C40 heteroalkyl, C1-C30 heteroalkyl, C1-C20 heteroalkyl, C2-C18 heteroalkyl, C3-C16 heteroalkyl, C4-C14 heteroalkyl, C5-C12 heteroalkyl, Ce-Cio heteroalkyl, Cs-Cio heteroalkyl, C4 heteroalkyl, Ce heteroalkyl, Cs heteroalkyl, C10 heteroalkyl, C12 heteroalkyl, Ci6 heteroalkyl, C20 heteroalkyl, or C24 heteroalkyl).
  • C1-C50 heteroalkyl e.g., C1-C40 heteroalkyl, C1-C30 heteroalkyl, C1-C20 heteroalkyl, C2-C18 heteroalkyl, C3-C16 heteroalkyl, C4-C14 heteroalkyl, C5-C12 heteroalkyl,
  • L 3 is optionally substituted C1-C50 heteroalkyl comprising a polyethylene glycol (PEG) moiety comprising 1-20 oxy ethylene (-O-CH2-CH2-) units, e.g., 2 oxyethylene units (PEG2), 3 oxyethylene units (PEG3), 4 oxyethylene units (PEG4), 5 oxyethylene units (PEG5), 6 oxyethylene units (PEG6), 7 oxyethylene units (PEG7), 8 oxy ethylene units (PEG8), 9 oxy ethylene units (PEG9), 10 oxy ethylene units (PEG10), 12 oxy ethylene units (PEG12), 14 oxy ethylene units (PEG14), 16 oxy ethylene units (PEG16), or 18 oxy ethylene units (PEG18).
  • PEG polyethylene glycol
  • L 3 is optionally substituted C1.50 heteroalkyl comprising a polyethylene glycol (PEG) moiety comprising 1-20 oxy ethylene (-O-CH2-CH2-) units or portions thereof.
  • PEG polyethylene glycol
  • L 3 comprises PEG3 as shown below:
  • L 3 is (CH2CH2O) m (CH2) w , and m and w are each independently an integer between 0 and 10 (inclusive), and at least one of m and w is not 0. [0245] In some embodiments, L 3 is substituted C1-C50 alkyl or substituted C1-C50 heteroalkyl, the substituent comprising a heteroaryl group (e.g., six-membered nitrogencontaining heteroaryl).
  • a heteroaryl group e.g., six-membered nitrogencontaining heteroaryl
  • A-L ⁇ l/jn-B can be represented by Formula I-a, or a metal complex thereof:
  • compounds are synthesized using bifunctional chelates that comprise a chelate, a linker, and a cross-linking group. Once the compound (e.g., radioimmunoconjugate) is formed, the cross-linking group may be absent from the compound (e.g., radioimmunoconjugate).
  • compounds e.g., radioimmunoconjugates
  • compounds comprise a cross-linking group instead of, or in addition to, the targeting moiety (e.g., in some embodiments, B in Formula I comprises a cross-linking group).
  • a cross-linking group is a reactive group that is able to join two or more molecules by a covalent bond.
  • Cross-linking groups may be used to attach the linker and chelating moiety to a therapeutic or targeting moiety.
  • Cross-linking groups may also be used to attach the linker and chelating moiety to a target in vivo.
  • the cross-linking group is an amino-reactive, methionine reactive or thiol -reactive cross-linking group, or a comprises sortase recognition sequence.
  • the amino-reactive or thiolreactive cross-linking group comprises an activated ester such as a hydroxysuccinimide ester, 2,3,5,6-tetrafluorophenol ester, 4-nitrophenol ester or an imidate, anhydride, thiol, disulfide, maleimide, azide, alkyne, strained alkyne, strained alkene, halogen, sulfonate, haloacetyl, amine, hydrazide, diazirine, phosphine, tetrazine, isothiocyanate, or oxaziridine.
  • an activated ester such as a hydroxysuccinimide ester, 2,3,5,6-tetrafluorophenol ester, 4-nitrophenol ester or an imidate
  • anhydride, thiol, disulfide maleimide
  • azide alkyne
  • strained alkyne strained alkene
  • the sortase recognition sequence may comprise of a terminal glycine-glycine- glycine (GGG) and/or LPTXG amino acid sequence, where X is any amino acid.
  • GGG terminal glycine-glycine- glycine
  • LPTXG amino acid sequence where X is any amino acid.
  • the present disclosure provides pharmaceutical compositions comprising compounds disclosed herein.
  • Such pharmaceutical compositions can be formulated for use in a variety of drug delivery systems.
  • One or more physiologically acceptable excipients or carriers can also be included in a pharmaceutical composition for proper formulation.
  • suitable formulations compatible for use with the present disclosure include those described in Remington ’s Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed., 1985.
  • suitable formulations compatible for use with the present disclosure include those described in Remington ’s Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed., 1985.
  • Langer Science. 249: 1527-1533, 1990.
  • compositions may be formulated for any of a variety of routes of administration discussed herein (See, e.g., the “Administration and Dosage” subsection herein), Sustained release administration is contemplated, by such means as depot injections or erodible implants or components.
  • an acceptable carrier preferably an aqueous carrier, e.g., water, buffered water, saline, or PBS, among others.
  • compositions contain pharmaceutically acceptable auxiliary substances to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, or detergents, among others.
  • pharmaceutical compositions are formulated for oral delivery and may optionally contain inert ingredients such as binders or fillers for the formulation of a unit dosage form, such as a tablet or a capsule.
  • pharmaceutical compositions are formulated for local administration and may optionally contain inert ingredients such as solvents or emulsifiers for the formulation of a cream, an ointment, a gel, a paste, or an eye drop.
  • provided pharmaceutical compositions are sterilized by conventional sterilization techniques, e.g., may be sterile filtered.
  • Resulting aqueous solutions may be packaged for use as is, or lyophilized. Lyophilized preparations can be, for example, combined with a sterile aqueous carrier prior to administration.
  • the pH of preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 6 and 7, such as 6 to 6.5.
  • Resulting compositions in solid form may be packaged, for example, in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules.
  • Pharmaceutical compositions in solid form can also be packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment.
  • the present disclosure provides methods of treatment comprising administering to a subject in need thereof a compound (e.g., radioimmunoconjugate) as disclosed herein.
  • a compound e.g., radioimmunoconjugate
  • a therapy (e.g., comprising a therapeutic agent) is administered to a subject.
  • the subject is a mammal, e.g., a human.
  • the subject has cancer or is at risk of developing cancer.
  • the subject may have been diagnosed with cancer.
  • the cancer may be a primary cancer or a metastatic cancer.
  • Subjects may have any stage of cancer, e.g., stage I, stage II, stage III, or stage IV with or without lymph node involvement and with or without metastases.
  • Provided compounds may prevent or reduce further growth of the cancer and/or otherwise ameliorate the cancer (e.g., prevent or reduce metastases).
  • the subject does not have cancer but has been determined to be at risk of developing cancer, e.g., because of the presence of one or more risk factors such as environmental exposure, presence of one or more genetic mutations or variants, family history, etc.
  • the subject has not been diagnosed with cancer.
  • the cancer is any cancer that comprises cells expressing EGFR and cMET.
  • the cancer is lung cancer, colorectal cancer, pancreatic cancer, or head and neck cancer.
  • Compounds (e.g., radioimmunoconjugates) and pharmaceutical compositions thereof disclosed herein may be administered by any of a variety of routes of administration, including systemic and local routes of administration [0259]
  • Systemic routes of administration include parenteral routes and enteral routes.
  • compounds (e.g., radioimmunoconjugates) or pharmaceutical compositions thereof are administered by a parenteral route, for example, intravenously, intraarterially, intraperitoneally, subcutaneously, intracranially, or intradermally.
  • compounds (e.g., radioimmunoconjugates) or pharmaceutical compositions thereof are administered intravenously.
  • compounds (e.g., radioimmunoconjugates) or pharmaceutical compositions thereof are administered by an enteral route of administration, for example, trans-gastrointestinal, or orally.
  • Local routes of administration include, but are not limited to, peritumoral injections and intratumoral injections.
  • compositions can be administered for radiation treatment planning, diagnostic, and/or therapeutic treatments.
  • the compound e.g., radioimmunoconjugate
  • the compound may be administered to a subject in a diagnostically effective dose and/or an amount effective to determine the therapeutically effective dose.
  • pharmaceutical compositions may be administered to a subject (e.g., a human) already suffering from a condition (e.g., cancer) in an amount sufficient to cure or at least partially arrest the symptoms of the disorder and its complications.
  • An amount adequate to accomplish this purpose is defined as a “therapeutically effective amount,” an amount of a compound sufficient to substantially improve at least one symptom associated with the disease or a medical condition.
  • an agent or compound that decreases, prevents, delays, suppresses, or arrests any symptom of the disease or condition would be therapeutically effective.
  • a therapeutically effective amount of an agent or compound is not required to cure a disease or condition but may, for example, provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered, or prevented, such that the disease or condition symptoms are ameliorated, or such that the term of the disease or condition is changed.
  • the disease or condition may become less severe and/or recovery is accelerated in an individual.
  • a subject is administered a first dose of a compound (e.g., radioimmunoconjugate) or composition in an amount effective for radiation treatment planning, then administered a second dose or set of doses of the compound (e.g., radioimmunoconjugate) or composition in a therapeutically effective amount.
  • a compound e.g., radioimmunoconjugate
  • a second dose or set of doses of the compound e.g., radioimmunoconjugate
  • the method of this invention typically comprises administering to a subject (e.g., a human) in need thereof a first dose of a compound or composition provided above in an amount effective for radiation treatment planning, followed by administering subsequent doses of a compound or composition provided above in a therapeutically effective amount.
  • the compound or composition administered in the first dose and the compound or composition administered in the second dose are the same.
  • the compound or composition administered in the first dose and the compound or composition administered in the second dose are different.
  • Therapeutically effective amounts may depend on the severity of the disease or condition and other characteristics of the subject (e.g., weight).
  • Therapeutically effective amounts of disclosed compounds (e.g., radioimmunoconjugates) and compositions for subjects (e.g., mammals such as humans) can be determined by the ordinarily-skilled artisan with consideration of individual differences (e.g., differences in age, weight and the condition of the subject).
  • disclosed compounds exhibit an enhanced ability to target cancer cells.
  • the effective amount of disclosed compounds e.g., radioimmunoconjugates
  • the effective amount of disclosed compounds is lower than (e.g., less than or equal to about 90%, 75%, 50%, 40%, 30%, 20%, 15%, 12%, 10%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of) the equivalent dose for a therapeutic effect of the unconjugated, and/or non-radiolab eled targeting moiety.
  • compositions disclosed herein including an effective amount can be carried out with dose levels and pattern being selected by the treating physician.
  • Dose and administration schedule can be determined and adjusted based on the severity of the disease or condition in the subject, which may be monitored throughout the course of treatment according to the methods commonly practiced by clinicians or those described herein.
  • This example describes the creation of bispecific antibody molecules that are capable of binding both EGFR and c-Met. 1.1 Isolation and identification of anti-cMET antibody 0021U3-B09
  • cMET-specific scFv antibodies were isolated from a large naive human scFv phage display library in a series of repeated panning selection cycles on recombinant mammalian expressed biotinylated monomeric human cMET (Medlmmune) essentially as described (Vaughan, 1996). ScFvs from the round 2 of the selection output were expressed in the bacterial periplasm and screened for their ability to inhibit the binding of the human cMET receptor with the HGF ligand in a HGF:cMET HTRF® (Homogeneous Time-Resolved Fluorescence) ligand receptor inhibitory binding assay. Top hits exhibiting strong inhibitory effect were selected and subjected to DNA sequencing.
  • variable framework regions of 0021U3-B09 were targeted specifically and altered to match the closest human germline sequence.
  • VH region seven amino acid residues were mutated to match the reference human germline sequence IGHVl-8*01.
  • VL region three residues were mutated to match the reference human germline sequence IGKVl-5*03. All residues in VH and VL regions were successfully changed to the germline residues without loss of activity.
  • 0021U3-B09 was affinity optimized using a hybridization-based mutagenesis method essentially as described (Kunkel 1985).
  • a large scFv library derived from 0021U3-B09 sequence was created by oligonucleotide- directed mutagenesis of the VH complementarity determining regions 3 (CDR3) using standard molecular biology techniques.
  • the library was subjected to affinity -based solution phase selections to select variants with a higher affinity to human and cynomolgus cMET antigens.
  • Crude scFv-containing periplasmic extracts from the CDR-targeted selection outputs were screened for improved inhibitory activity in the HGF: cMET HTRF® binding assay.
  • Variants exhibiting significantly improved inhibitory effect compared to parent 0021U3-B09, were subjected to DNA sequencing and unique genes were converted to human IgG2.
  • the purified antibodies were then ranked based on their inhibitory effect.
  • the most potent antibody, B09-57 was selected for further characterization.
  • EGFR-specific scFv antibodies were isolated from a large naive human scFv phage display library in a series of repeated panning selection cycles on recombinant mammalian expressed biotinylated monomeric human EGFR (Medlmmune) essentially as described (Vaughan, 1996). ScFv-displaying phage from the round 3 of the selection output were screened for their binding to human and cynomolgus EGFR in ELISA. Top hits showing cross reactivity were selected and subjected to DNA sequencing. Unique genes were then converted to human immunoglobulin G1 (IgGl ) antibodies and produced in mammalian cells essentially as described (Persic, 1997). The purified antibodies were then ranked based on their binding to the EGFR-expressing cell line, A431, by flow cytometry. Antibody Tdev- 0004 exhibiting specific cell binding was selected for further characterization.
  • IgGl immunoglobulin G1
  • Variant RAA22 and QD6, were derived by optimizing the anti-EGFR Tdev-0004 mAb.
  • H4 was used as a template sequence for the affinity optimization.
  • Variant H4 was affinity optimized by parsimonious mutagenesis of all six CDRs using a QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent), according to the manufacturer’s instructions.
  • VH and VL libraries Single amino acid mutagenized VH and VL libraries were expressed in bacteria as Fab fragments and screened for improved binding to human and cynomolgus EGFR in ELISA. Variants exhibiting improved binding compared to parent H4 were subjected to DNA sequencing and unique genes were converted to human IgGl. Variant RAA22 was identified with a single mutation in CDRH3. To further improve the affinity, individual positive mutations were combined to create a combinatorial library that was screened for variants with enhanced binding to human and cynomolgus EGFR. Variant QD6 was identified with four combined mutations in CDRL2, CDRL3 and CDRH3.
  • variable domains of the anti-cMET mAb B09-57 and anti-EGFR mAbs RAA22 and QD6 were utilized for the construction of monovalent bispecific anti-EGFR/cMET antibodies on the backbone of the DuetMab platform (Mazor, 2015).
  • the VH gene of the anti-cMET B09-57 was inserted into a human gamma- 1 constant heavy chain carrying the “Knob” mutation (T366W) and the alternative interchain cysteine mutations (F126C and C219V).
  • the VL gene of B09-57 was inserted in frame into a human Kappa constant domain carrying the corresponding alternative interchain cysteine mutations (S121C and C214V) designed to pair with the “Knob” heavy chain.
  • the VH genes of the anti-EGFR RAA22 and affinity optimized QD6 were inserted into a human gamma- 1 constant heavy chain carrying the “Hole” mutations (T366S, L368A, and Y407V), while the VL genes of RAA22 and B09-57 were inserted in frame into a human Lambda constant domain designed to pair with the “Hole” heavy chain.
  • the assembled monovalent bispecific anti-EGFR/cMET DuetMab antibodies were designated as RAA22/B09-57 and QD6/B09-57 (FIG. 1). DuetMab antibodies were produced from mammalian cells as previously described (Mazor, 2017).
  • RAA22 and B09 with the TM introduced has the amino acid sequences set forth in the following table:
  • This example tests various biochemical and biophysical properties of the RAA22, QD6 and B09-57 monoclonal antibodies and RAA22/B09-57 and QD6/B09-57 bispecific antibodies molecules, including their binding affinity to EGFR and c-Met, respectively and their ability to bind both antigens simultaneously.
  • Test and control article antibodies were prepared at 5-20 nM in instrument buffer (HBS-EP buffer; 0.0 IM HEPES, pH 7.4, 0.15M NaCl, 3mM EDTA, and 0.005% P-20), along with 3-fold serial dilutions of purified EGFR (0.27-200 nM human, 0.4-900 nM cyno, and 4-1000 nM murine) or cMET proteins (0.27-66 nM human and 0.27- 22 nM cyno) in instrument buffer.
  • a sequential approach was utilized for kinetic measurements.
  • Antibodies were first injected over the capture surface, at a flow rate of 10 pL/minute. Once the binding of the captured antibody stabilized, a single concentration of the analyte was injected over both capture and reference surfaces, at a flow rate of 75 pL/minute. The resulting binding response curves yielded the association phase data.
  • Mouse cMET ND a ND not determined.
  • Kinetic measurements to soluble monomeric forms of EGFR and cMET were performed using a BIACore instrument. Kd were calculated as the ratio of koff/kon from a non-linear fit of the data.
  • bispecific antibody molecule QD6/B09-57 binds human cMet with a high affinity ( ⁇ 2 nM Kd) and human EGFR with a high affinity ( ⁇ 2 nM Kd)
  • bispecific antibody molecule RAA22/B09-57 binds human c-Met with a similarly high affinity ( ⁇ 2 nM Kd) but binds human EGFR with a reduced affinity ( ⁇ 45 nM Kd) in comparison to QD6/B09-57.
  • R374 a non-binding IgGl isotype control antibody
  • B09 anti-cMET antibody
  • QD6 anti-EGFR antibody
  • RAA22 anti-EGFR antibody
  • QD6/B09 bispecific EGFR/c-MET DuetMAb
  • RAA22/B09 bispecific EGFR/c-MET DuetMAb
  • PaniX anti-EGFR antibody
  • MetMab anti-cMET antibody
  • Mabl 1311 anti-HER4 antibody
  • Wells were incubated with 50 microliters of the indicated primary antibodies diluted in PBS-T in a 1 :3 dilution series, starting at 10 pg/mL and ending at 0.002 pg/mL, except for the HER4 binding mAb control, MAB 1131, for which the series started at 1 pg/mL.
  • the wells were washed 4 times in PBS-T, then 50 pl of goat anti-human Fab HRP- labeled secondary antibody, diluted 1 :5000 in PBS-T, was added to each well and incubated for one hour at room temperature. 50 microliters of TMB substrate solution was added to all wells and incubated at room temperature for 5-30 min, until intense signal was observed in the positive control wells.
  • ELISA assays were carried out as described above. As shown in FIG. 3A, the high affinity EGFR IgG, QD6, as well as the monovalent bispecific EGFR/cMET DuetMAb, QD6/B09, bound to human, cynomolgus monkey, and mouse EGFR and gave robust signals in the ELISA assay.
  • Target expression in normal, non-tumor tissues can lead to toxicities that reduce the therapeutic window of the antibody conjugates by decreasing payload delivery to the target tissue.
  • the design of the bispecific antibodies or antigen-binding fragments thereof of compounds (e.g., radioimmunoconjugates) of the present disclosure are intended to minimize the impact of the conjugate in normal tissues that exhibit little or no co-expression of the targets while maximizing the delivery of the antibody molecule (i.e., the payload delivery vehicle) to tumor cells that co-express the two targets.
  • the antibodies that were labeled were: R347 IgGl isotype control, monovalent bispecific control antibodies anti-EGFR antibody RAA22/R347 and anti- cMET B09/R347, as well as EGFR/cMET monovalent bispecific antibody RAA22/B09.
  • NCI-H1975 lung cancer cells which co-express modest levels of EGFR (-33,000 relative receptor density) and cMET (-50,000 relative receptor density), were plated into clear bottomed, black walled 96-well assay plates in 100 microliter volumes at a density of 2xl0 5 cells/mL in RPMI growth medium supplemented with 10% fetal bovine serum. The plates were cultured in a humidified incubator overnight at 37°C and 5% CO2.
  • the plates were then chilled on ice for 30 min prior to addition of pHAb labeled bispecific and monovalent control antibodies at various concentrations in pre-chilled growth medium.
  • the cultures were chilled on ice for another 30 minutes, and then the fluorescence was read on an Operetta High Content Imaging system using the Cy3 filter and this initial reading was designated as time zero.
  • the plates were moved back to the 37°C incubator and additional readings were taken at 3, 6, 24, 30 and 48 hours.
  • FIG. 4 A representative internalization experiment using pHAb labeled mAbs at 1.25 pg/mL to treat NCI Hl 975 cells is shown in FIG. 4.
  • the non-binding IgGl isotype control antibody, R347 showed no detectable fluorescence at any time point.
  • the EGFR/cMET bispecific antibody, RAA22/B09 exhibited intracellular fluorescence by 3 hours and fluorescence intensity continued to increase out to 48 hours post treatment.
  • the monovalent EGFR binding control antibody, RAA22/R347 showed very weak fluorescence starting at 24 hours, which did not increase dramatically by 48 hours.
  • the monovalent monospecific cMET binding control antibody, B09/R347 showed modest fluorescence at 24 hours, increasing further by 48 hours.
  • the intensity of the fluorescent signal of the monospecific cMET antibody was modest compared to the bispecific RAA22/B09, suggesting that the bispecific antibody has greater internalization efficiency than the monospecific parental antibody in the dual target expressing cell line tested here.
  • the difference between bispecific antibody and monospecific controls was even more striking (FIG. 5).
  • the monospecific antibodies showed very little fluorescence, even at 48 hours, while the bispecific RAA22/B09 antibody again showed intracellular fluorescence by 3 hours and fluorescence intensity continued to increase out to 48 hours post treatment.
  • the monospecific parental antibodies show a reduced uptake and fluorescence intensity compared to the bispecific antibody.
  • a logical extension of these conclusions is to suggest that the bispecific antibody might behave more like the monospecific antibodies in tissues that express only one but not both targets, which is generally true for EGFR and cMET.
  • the pHAb labeled lowered affinity EGFR control mAb, RAA22/R347 exhibited negligible uptake and fluorescence. This reduced binding to EGFR could minimize the impact of the antibody conjugate in normal tissues, such as the skin, which express significant levels of EGFR but little or no cMET.
  • H1975 and HCC827 cells were from ATCC.
  • RAA22/B09, QD6/B09, and singlearm derivatives were from Medlmmune.
  • QD6/B09 and single arm specific controls QD6/IgG and B09/IgG, with IgG Fab arms were derived from the non-specific human IgGl NMGC were from Medlmmune.
  • RAA22/B09 and single-arm specific controls RAA22/IgG and B09/IgG derived from the non-specific human IgGl R347, were from Medlmmune.
  • RPMI 11875-093
  • HEPES 15630106
  • sodium pyruvate 11360070
  • AlexaFluor® 647 A-20186
  • Monoclonal Antibody Labeling Kits ZebaTM Spin Desalting Columns (87767), and CellTrackerTM Blue CMAC (C2110) were from Life Technologies (Carlsbad, CA).
  • Accutase Cell Detachment Solution (423201) was from BioLegend (San Diego, CA).
  • HyClone heat-inactivated fetal bovine serum SH30071.03HI
  • PBS (21-040) was from Corning Incorporated (Corning, NY).
  • FcR Blocking Reagent 130-059-901 was from Miltenyi Biotec Inc. (Auburn, CA). Polypropylene round-bottomed tubes (352063) were from BD Biosciences (San Jose, CA). CellCarrier 384-well microplates were from PerkinElmer Inc. (Cat# 6007550, Waltham, MA).
  • Monoclonal antibodies were conjugated with AlexaFluor-647 dyes using the antibody labeling kits according to manufacturer instructions.
  • Adherent H1975 or HCC827 cells were cultured in T-75 flasks in the CO2 incubators using media RPMI-1640 containing 10% fetal bovine serum (FBS) to 80-90% confluency after initial seeding.
  • FBS fetal bovine serum
  • adherent monolayers grown in T-75 flasks were dissociated into cell suspension using Accutase. Detached cells were washed twice with lx PBS using centrifugation at 300xg for 5 min. Cells were then resuspended into phenol-free RPMI at concentration of 2x 106 cells/mL and used for staining.
  • cells were resuspended in phenol -free RPMI containing 100 mM HEPES, 1 mM sodium pyruvate, and 1% FBS. Cells were transferred into multiple wells of a 384-well imaging plate at a density of 5,000 cells per well, and briefly centrifuged at 2,200 rpm for 2 min at 4°C prior to image acquisition.
  • Stained cells in imaging plates were either imaged on an Opera confocal fluorescence imaging system as previous described previously (Vainshtein, 2015) or transferred onto a Zeiss Axio Observer.Zl inverted microscope with 40X/1.2NA LCIPlan Apo objective (Carl Zeiss Microscopy, Thornwood, NY).
  • the imaging environment was kept at 37°C at 5% CO2 and 70% humidity using an Incubator XLmulti S DARK (PeCon Gmbh, Erbach, Germany). Samples were illuminated by 405, 488, 561, and 63 nm solid-state lasers (Carl Zeiss Microscopy, Thornwood, NY).
  • a series of images was acquired at indicated times using a Yokogawa CSU-X1 Spinning Disk Unit (Yokogawa Electric Corporation, Tokyo, Japan) with Evolve 512 EMCCD (Photometries, Tuscon, AZ). Prior to image acquisition, exposure parameters, such as laser power, exposure times, camera gain, etc., were determined using an aliquot of the stained cells. Images were processed using ZEN 2.3 (Carl Zeiss Microscopy, Thornwood, NY) and analyzed using Columbus software (PerkinElmer, Waltham, MA).
  • the algorithm used for quantification of antibody internalization was described previously (Vainsthein, 2015), with the following updates and modifications.
  • the reference channel used for iterative image processing originated from the CellTrackerTM Blue CMAC (CTB) staining of cells. Signal channel still derived from the antibody-AlexaFluor-647 channels of the imagers. Images were processed by the algorithm using algorithm-defined parameters, which were initially set as default values and then optimized for each cell type and experiment. CTB staining of the image was used to identify cells using thresholding to detect a region on the image having a higher intensity than its surrounding based excluding areas with fluorescence intensity signals below the threshold. The remaining identified cell objects were designated “Total Cell”.
  • Cells were further selected filtering on morphology properties area (objects between 120-600 pm 2 ) and roundness (>0.5). “Membrane Region” and “Cytoplasm Region” in the accepted cells were then constructed around the object boundaries using algorithm-defined parameters. Fluorescence intensity in each region was used to monitor antibody-associated AlexaFluor-647 signals. The fluorescence intensities of each region were reported as the mean of the sum of all pixels in accepted cells.
  • FIG. 6B shows very comparable internalization kinetic for QD6/B09 and RAA22/B09 with the half-times of 37.5 ⁇ 10.6 min and 43.2 ⁇ 15.5, respectively.
  • the B09/IgG construct showed very small level of internalization (FIG. 7B, right).
  • the rapid and extensive decrease of the membrane signal corresponded to a very moderate increase of the cytoplasm signal, likely due to extensive dissociation of pre-bound B09/IgG from c-MET receptor on the cell surface.
  • the dissociation of the antibody subsequently resulted in modest internalization of B09/IgG.
  • RAA22/B09 DuetMab showed internalization profiles very different when compared to its single-arm control antibodies. As seen in FIG.
  • cytoplasmic intensity values were 10.98- and 4.70-fold higher for RAA22/B09 DuetMab than RAA22- IgG and B09-IgG, respectively. While inefficient internalization of B09/IgG maybe attributed to its pronounced dissociation (discussed above), RAA22/IgG did undergo rapid internalization. However, due to the lower affinity of the EGFR-arm, the number of RAA22/IgG molecules were 10.98-fold less (based on fluorescent intensity) than for the RAA22-B09 DuetMab. The markedly increased amount of duet RAA22/B09 mAb entering the cytoplasm as opposed to the single-arm constructs demonstrated that both antibody arms must engage with target receptors to drive internalization.
  • Lutetium- 177 can be obtained from ITM Medical Isotopes as lutetium trichloride in a 0.05 N hydrochloric acid solution; indium-111, as indium trichloride in a 0.05 N hydrochloric acid solution, can be obtained from BWXT; and actinium-225 can be obtained as actinium-225 trinitrate from Oak Ridge National Laboratories or actinium-225 trichloride from Canadian Nuclear Laboratories.
  • Analytical HPLC-MS can be performed using a Waters Acquity HPLC-MS system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager (samples cooled to 10°C), a Water Acquity Column Manager (column temperature 30°C), a Waters Acquity Photodiode Array Detector (monitoring at 254 nm and 214 nm), a Waters Acquity TQD with electrospray ionization and a Waters Acquity BEH C18, 2.1 x50 (1.7 pm) column.
  • a Waters Acquity HPLC-MS system comprised of a Waters Acquity Binary Solvent Manager, a Waters Acquity Sample Manager (samples cooled to 10°C), a Water Acquity Column Manager (column temperature 30°C), a Waters Acquity Photodiode Array Detector (monitoring at 254 nm and 214 nm),
  • Preparative HPLC can be performed using a Waters HPLC system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 254 nm and 214 nm) and a Waters XBridge Prep phenyl or C18 19x 100 mm (5 pm) column.
  • a Waters HPLC system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 254 nm and 214 nm) and a Waters XBridge Prep phenyl or C18 19x 100 mm (5 pm) column.
  • Analytical Size Exclusion Chromatography can be performed using a Waters system comprised of a Waters 1525 Binary HPLC pump, a Waters 2489 UV/Visible Detector (monitoring at 280 nm), a Bioscan Flow Count radiodetector (FC-3300) and TOSOH TSKgel G3000SWxl, 7.8x300 mm column.
  • MALDI-MS positive ion
  • MALDI-MS can be performed using a MALDI Bruker Ultrafl extreme Spectrometer.
  • Radio thin-layer chromatography can be performed with Bioscan AR- 2000 Imaging Scanner, and can be carried out on iTLC-SG glass microfiber chromatography paper (Agilent Technologies, SGI0001) plates using citrate buffer (0.1 M, pH 5.5).
  • a bifunctional chelate, 4- ⁇ [l 1-oxo-l l-(2,3,5,6- tetrafluorophenoxy)undecyl]carbamoyl ⁇ -2-[4,7, 10-tris(carboxymethyl)-l ,4,7, 10- tetraazacyclododecan-l-yl]butanoic acid (Compound B), can be synthesized according to the scheme provided in FIG. 11.
  • EXAMPLE 8 Conjugation and radiolabeling for synthesis of radioimmunoconjugates comprising EGFR-cMET antibody
  • a 133 mL sterile solution container was charged with a PBS (phosphate buffered saline) solution of EGFR-cMET monoclonal bispecific antibody RAA22/B09 DuetMab (58.8 mL; 5.1 mg/mL; 300 mg), followed by 5.88 mL carbonate buffer (1.0 M, pH 9.5) and 2.83 mL of a 0.001 M HC1 solution of Compound C (7.7 equiv.; 17.3 mg in 3.00 mL; this solution was prepared immediately prior to use). The pH of the resulting mixture was determined to be about 9.5-10 by pH strip. The reaction was allowed to react for two hours at room temperature.
  • PBS phosphate buffered saline
  • Ammonium acetate (28.1 g) was added to the reaction mixture, the resulting solution was then loaded onto a 5 mL Cytiva HiTrap Butyl HP (HIC) cartridge (the HIC cartridge was first pretreated with sodium acetate buffered saline with tween (SABST; 50 mL) followed by ammonium acetate solution (50 mL; 0.42 g/mL). The HIC cartridge was washed with the ammonium acetate solution (10 mL), then the product eluted with SABST (about 10 mL). The product solution was diluted to ca.
  • HIC Cytiva HiTrap Butyl HP
  • a chelate-to-antibody ratio (CAR) of 5.3 was determined using Matrix- Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry, and was calculated from the difference in the mass-to charge ratio between the EGFR-cMET antibody and immunoconjugate Compound D.
  • MALDI-TOF Matrix- Assisted Laser Desorption Ionization Time-of-Flight
  • the product fractions were eluted using SABST and combined.
  • SABST solutions of sodium L-ascorbate and DTPA were added, and analysis of the resulting formulation (about 10 mM sodium L- ascorbate, 1 mM DTPA) by iTLC and SEC-HPLC at EOS indicated the formation of Compound F (448 pL, 0.680 mg/mL, 0.053 mCi/mg specific activity, >99 % radiochemical purity, and >99 % chemical purity).
  • EXAMPLE 9 In vitro binding of [ 177 Lu]-Compound C-anti-EGFR-cMET conjugate [0327] A study was conducted to evaluate the receptor binding affinity of [ 177 Lu]- Compound C-anti-EGFR-cMET conjugate, z.e., Compound E, with four different cell lines: HCC827 cells, HT29 cells, H441 cells, and H1975 cells. This study followed the procedures described below.
  • the purpose of this assay was to ensure that the radioimmunoconjugates maintained the binding characteristics of the native antibody in EGFR and/or cMET expressing cell lines including HT29, H441, HT29, HCC827, and H1975.
  • cells (1.5-2xl0 5 ) were seeded in 48-well microplates in 500 pL supplemented medium.
  • cells were washed with PBS once and then treated with increasing concentrations of Compound E (0.05 nM to 100 nM) in the absence and presence of 4 pM cold antibody [total binding (TB) and non-specific binding (NSB) respectively].
  • This internalization assay was designed to determine the degree of cell retention of radiolabeled - linker antibody derivatives.
  • the assay relies on the inherent ability of the EGFR-cMET receptor to internalize when bound to antibody and the ability to track radiolabeled compounds.
  • a constant amount of radioimmunoconjugate is incubated with four different cell lines for a fixed duration of time and residualizations are determined by calculating the amount of internalized radioactivity as a percentage of the total cell- associated activity.
  • EXAMPLE 11 In vivo biodistribution of [ 177 Lu]-Compound C-anti-EGFR-cMET conjugate in various animal models [0335] Five different cell line xenograft mouse models were used to assess the in vivo biodistribution of [ 177 Lu]-DOTA-anti-EGFR-cMET conjugate, i.e., Compound E, following the below protocol.
  • Tumor inoculations Cells were washed with PBS and detached with 0.25% trypsin EDTA. The harvested cells were resuspended in a 1 : 1 mixture of PBS and Matrigel (BD, Oakville ON) at the following concentrations:
  • HCC827 50xl0 6 cells/mL HT29: 20xl0 6 cells/mL H1975: 50xl0 6 cells/mL H292: 30xl0 6 cells/mL H441 : 50xl0 6 cells/mL
  • Radioactive injections started at about 7-10 days post inoculation when tumor volume reached to 150-200mm3, except for HCC827 xenografts that reached the same size at 3 weeks post inoculation.
  • Results were expressed as the percentage injected dose per gram of tissue (% ID/g) and are depicted in FIGs. 16A-16E.
  • Biodistribution study of Compound E showed the typical biodistribution profile for IgGs with acceptable levels of uptake in normal organs.
  • the highest tumor uptake (%ID/g) was observed in H292> H441> HT29 and H1975 xenografts [about 75% (96 h, 168 h), about 35% (48 h, 96 h), about 29% (48 h, 96 h), and about 20% (48 h, 96 h), respectively].
  • HCC827 xenograft model was not pursued for therapy study due to slow tumor growth rate.
  • Compound F 225 Ac radiolabeled EGFR-cMET antibody
  • Therapeutic efficacy studies were carried out using H441, HT29 and H1975 tumor xenografts.
  • Compound F was dosed at 50 - 400 nanocuries (nCi) of activity formulated in 20 mM sodium citrate pH 5.5, 0.82 % NaCl, and 0.01 % Tween - 80 buffer.
  • non-radiolab eled, non-conjugated antibody was administered at a protein mass equivalent corresponding to the highest radioactivity dose of Compound F tested in a study.
  • Tumor measurements were taken 2 - 3 times per week for at least 60 days with vernier calipers in two dimensions. Tumor length was defined as the longest dimension, width was measured perpendicular to the tumor length. At the same time animals were weighed. Overall body condition and general behavior were assessed daily.
  • Tumor volume (mm) was calculated from caliper measurements as an ellipsoid: Tumor growth was expressed as relative tumor volume (RTV) which is tumor volume measured on day X divided by the tumor volume measured on the day of dosing.
  • RTV relative tumor volume

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PCT/US2022/082021 2021-12-20 2022-12-20 Egfr-cmet–targeted compounds and uses thereof Ceased WO2023122588A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2024007596A MX2024007596A (es) 2021-12-20 2022-12-20 Compuestos dirigidos a egfr-cmet y usos de estos.
IL313333A IL313333A (en) 2021-12-20 2022-12-20 EGFR-CMET-Targeted Compounds and Their Uses
CN202280092041.0A CN118765273A (zh) 2021-12-20 2022-12-20 靶向EGFR-cMET的化合物及其用途
CR20240254A CR20240254A (es) 2021-12-20 2022-12-20 Compuestos dirigidos a egfr-cmet y usos de estos
AU2022419564A AU2022419564A1 (en) 2021-12-20 2022-12-20 Egfr-cmet–targeted compounds and uses thereof
CA3244030A CA3244030A1 (en) 2021-12-20 2022-12-20 COMPOUNDS TARGETED BY EGFR-CMET AND THEIR USES
KR1020247024103A KR20240125970A (ko) 2021-12-20 2022-12-20 EGFR-cMET-표적화 화합물 및 이의 용도
EP22912656.0A EP4452954A2 (en) 2021-12-20 2022-12-20 Egfr-cmet-targeted compounds and uses thereof
US18/721,647 US20250121104A1 (en) 2021-12-20 2022-12-20 Egfr-cmet-targeted compounds and uses thereof
JP2024537033A JP2025500944A (ja) 2021-12-20 2022-12-20 ＥＧＦＲ－ｃＭＥＴ標的化合物及びその使用
CONC2024/0008733A CO2024008733A2 (es) 2021-12-20 2024-06-28 Compuestos dirigidos a egfr-cmet y usos de estos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291910P 2021-12-20 2021-12-20
US63/291,910 2021-12-20

Publications (2)

Publication Number Publication Date
WO2023122588A2 true WO2023122588A2 (en) 2023-06-29
WO2023122588A3 WO2023122588A3 (en) 2023-09-21

Family

ID=86903719

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/082021 Ceased WO2023122588A2 (en) 2021-12-20 2022-12-20 Egfr-cmet–targeted compounds and uses thereof

Country Status (15)

Country Link
US (1) US20250121104A1 (https=)
EP (1) EP4452954A2 (https=)
JP (1) JP2025500944A (https=)
KR (1) KR20240125970A (https=)
CN (1) CN118765273A (https=)
AR (1) AR128052A1 (https=)
AU (1) AU2022419564A1 (https=)
CA (1) CA3244030A1 (https=)
CL (1) CL2024001832A1 (https=)
CO (1) CO2024008733A2 (https=)
CR (1) CR20240254A (https=)
IL (1) IL313333A (https=)
MX (1) MX2024007596A (https=)
TW (1) TW202333799A (https=)
WO (1) WO2023122588A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044552A1 (en) * 2022-08-22 2024-02-29 Abdera Therapeutics Inc. Vhh antibody dota conjugates
WO2025036355A1 (zh) * 2023-08-14 2025-02-20 明慧医药（杭州）有限公司 抗c-MET纳米抗体及其用途
WO2025180474A1 (zh) * 2024-03-01 2025-09-04 烟台蓝纳成生物技术股份有限公司 一种二价双特异性抗体、抗体偶联核素药物及其应用
WO2025195500A1 (zh) * 2024-03-22 2025-09-25 康源博创生物科技(北京)有限公司 一种多肽及其用于构建包含共同轻链的双特异性抗体中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7090204B2 (ja) * 2018-07-19 2022-06-23 イーライ リリー アンド カンパニー 免疫チェックポイントを標的とする二重特異性抗体
CN114945594B (zh) * 2019-12-23 2024-11-26 株式会社Lg化学 抗lilrb1抗体及其用途
KR20220157464A (ko) * 2020-03-23 2022-11-29 퓨전 파마슈티칼즈 인크. Fgfr3-표적화된 방사선면역접합체 및 그의 용도
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044552A1 (en) * 2022-08-22 2024-02-29 Abdera Therapeutics Inc. Vhh antibody dota conjugates
WO2025036355A1 (zh) * 2023-08-14 2025-02-20 明慧医药（杭州）有限公司 抗c-MET纳米抗体及其用途
WO2025180474A1 (zh) * 2024-03-01 2025-09-04 烟台蓝纳成生物技术股份有限公司 一种二价双特异性抗体、抗体偶联核素药物及其应用
WO2025195500A1 (zh) * 2024-03-22 2025-09-25 康源博创生物科技(北京)有限公司 一种多肽及其用于构建包含共同轻链的双特异性抗体中的应用

Also Published As

Publication number Publication date
CL2024001832A1 (es) 2024-11-22
TW202333799A (zh) 2023-09-01
CA3244030A1 (en) 2023-06-29
EP4452954A2 (en) 2024-10-30
CN118765273A (zh) 2024-10-11
JP2025500944A (ja) 2025-01-15
MX2024007596A (es) 2024-07-09
KR20240125970A (ko) 2024-08-20
AR128052A1 (es) 2024-03-20
IL313333A (en) 2024-08-01
CO2024008733A2 (es) 2024-07-29
WO2023122588A3 (en) 2023-09-21
AU2022419564A1 (en) 2024-07-04
CR20240254A (es) 2025-01-13
US20250121104A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
US20250121104A1 (en) Egfr-cmet-targeted compounds and uses thereof
EP4423137A1 (en) Claudin 18.2-targeted compounds and uses thereof
TW202304532A (zh) 治療癌症之方法
WO2021207086A1 (en) Tem-1-targeted radioimmunoconjugates and uses thereof
KR20240099208A (ko) EGFRvIII-표적화 화합물 및 그의 용도
JP2023518818A (ja) Ｆｇｆｒ３に標的化されたラジオイムノコンジュゲートおよびその使用
US20240350682A1 (en) Steap2-targeted compounds and use thereof
WO2024216389A9 (en) Claudin 18.2-targeted compounds and uses thereof
WO2024229575A9 (en) Use of radiopharmaceuticals for treatment of cancer
AU2022379928A1 (en) Methods of treating cancer
HK40084697A (en) Fgfr3-targeted radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22912656

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202491170

Country of ref document: EA

Ref document number: 313333

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2024537033

Country of ref document: JP

Ref document number: MX/A/2024/007596

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2401004071

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 12024551530

Country of ref document: PH

Ref document number: 2022419564

Country of ref document: AU

Ref document number: 812233

Country of ref document: NZ

Ref document number: P2024-01612

Country of ref document: AE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024012350

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: NC2024/0008733

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 202417051010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20247024103

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022912656

Country of ref document: EP

Effective date: 20240722

WWP Wipo information: published in national office

Ref document number: NC2024/0008733

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 11202403896Q

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202280092041.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22912656

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112024012350

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240618

WWP Wipo information: published in national office

Ref document number: 18721647

Country of ref document: US